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Abstract: In many ways, atherosclerosis is a chronic inflammatory disorder and this issue is confirmed by recent investigations of that 
have focused on inflammation, providing new insight into mechanisms of disease. Several recent studies have addressed the role of 
chemokines in leukocyte accumulation in atherosclerosis, extending our knowledge and understanding of the complex and cell type-
specific functions of chemokines in atherosclerosis. Activated T-lymphocytes within the atherosclerotic vessel wall express the CD40 
ligand surface molecule, known to play a major role in several immunological pathways. In addition to activated T-lymphocytes, func-
tional CD40 and CD40L are coexpressed by human vascular endothelial cells, smooth muscle cells and human macrophages in vitro as 
well as in situ in human atherosclerotic lesions. Recent studies indicate that CD40L activates atheroma-associated cells by promoting the 
expression of molecules thought to be involved in atherosclerosis, such as adhesion molecules, cytokines, matrix metalloproteinases, and 
tissue factor. Atherosclerosis starts with an innate immune response involving the recruitment and activation of monocytes   macrophages 
that respond to an excessive accumulation of modified lipids within the arterial wall, followed by an adaptive immune response involving 
antigen-specific T lymphocytes. Effector T cells recognize modified auto-antigens such as oxidized LDL and heat shock proteins (i.e. 
HSP-60) that are presented by antigen-presenting cells such as macrophages or dendritic cells. The accumulation of inflammatory cells 
within the arterial wall leads to local production of chemokines, interleukins and proteases that enhance the influx of monocytes and 
lymphocytes, thereby promoting the progression of atherosclerotic lesions Recent reports have helped explain some of these questions by 
pointing to a role of contact dependent interaction between CD40 and CD40 ligand (CD40L, renamed CD154) as a stimulus for 
atheroma-associated cells. Also Macrophages play important roles in the progression of atherosclerosis by exhibiting unique characteris-
tics under the various stimuli, evolving the plaque instability, thrombus formation and remodeling. Macrophage recruitment by abnormal 
endothelium over developing atherosclerotic plaques, is aided by endothelial expression of adhesion molecules (ICAM-1, VCAM, 
ELAM). The knowledge of atherosclerosis as an inflammatory disease offers the opportunity to develop novel therapeutic strategies 
targeting the inflammatory component of the disease.  
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INTRODUCTION 
 Atherosclerosis is a process of progressive thickening and hard-
ening of the walls of medium-sized and large arteries as a result of 
fat deposits on their inner lining. It is a pathological condition that 
underlies several important adverse vascular events including coro-
nary artery disease (CAD), stroke, and peripheral arterial disease, 
responsible for most of the cardiovascular morbidity and mortality 
in the Western world today. In many ways, atherosclerosis is a 
chronic inflammatory disorder and this issue is confirmed by recent 
investigations of that have focused on inflammation, providing new 
insight into mechanisms of disease [1-4]. 
 The lesions of atherosclerosis occur principally in large and 
medium-sized elastic and muscular arteries and can lead to ische-
mia of the heart, brain, or extremities, resulting in infarction. 
 The concept of the involvement of inflammation in atheroscle-
rosis has spurred the discovery and adoption of inflammatory bio-
markers for cardiovascular risk prediction. C-reactive protein is 
currently the best validated inflammatory biomarker; in addition, 
soluble CD40 ligand, adiponectin, interleukin 18, and matrix metal-
loproteinase 9 may provide additional information for cardiovascu-
lar risk stratification and prediction. This trend of new definitions of 
atherosclerosis appeared in the mid 1970s,when Russel Ross devel-
oped his popular “response to injury” hypothesis of atherogenesis, 
postulating that atherosclerotic lesions arise as a result of focal 
injury to the arterial endothelium, followed by adherence and ag-
gregation of platelets [5] More recently a review by Ross [6] de-
scribed recent advances understanding of the cellular composition 
of the lesions of atherosclerosis and has emphasized the interactions 
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among the cells involved in lesion formation during hypercholes-
terolemia reporting the involvement of inflammatory cells such as 
leukocytes and macrophages.  
 The earliest type of lesion, the so-called fatty streak is a pure 
inflammatory lesion, consisting only of monocyte-derived macro-
phages and T lymphocytes [7,8]. 
 Substantial evidence has been accumulated to establish the 
notion that atherosclerosis is an inflammatory disease. The continu-
ous immigration and infiltration of activated macrophages and T 
cells into and within atherosclerotic lesions are prominent features 
in both human and experimental atherosclerotic disease. The re-
cruitment of these cells to lesions is guided by endothelial leuko-
cyte adhesion molecules and chemoattractants. In keeping with this 
formulation, the atherosclerotic plaque has as its major components 
macrophages, cells of the adaptive immune system, smooth muscle 
cells, and matrix components. As with most chronic inflammatory 
reactions, the cells of the immune system have the potential to sig-
nificantly influence the outcome of the inflammation. 
 The atherosclerotic plaque is notable for its focal nature, being 
mostly encountered in regions of the macrovasculature subject to 
disturbed flow hemodynamics.  
 On this basis it’s possible to define atherosclerosis as a chronic 
inflammatory disease of the arterial wall where both innate and 
adaptive immune responses contribute to disease initiation and 
progression. Atherosclerotic lesions are characterized by the infil-
tration of immune competent cells such as macrophages and T-
lymphocytes, the proliferation of intimal cells of the arterial wall, 
the accumulation of lipids and the deposition of extracellular matrix 
components [see Fig. (1)]. For some years, endothelial cells, 
smooth muscle cells, and macrophages have been accorded crucial 
roles in the process of atherosclerosis. The mechanisms by which 
these cells contribute to atherosclerosis include augmented expres-
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sion of adhesion molecules, as well as secretion of proinflammatory 
cytokines, matrix metalloproteinases, and tissue factor within hu-
man and experimental atheroma [see Fig. (2)]. Much evidence sup-
ports the role of tissue factor in inciting the thrombosis that causes 
most acute coronary syndromes. Macrophage content and expres-
sion of tissue factor correlate with rupture and instability of the 
atherosclerotic plaque [see Fig. (3)]. Matrix metalloproteinases can 
digest the plaque's extracellular matrix, and thus impair its stability. 
Plaque rupture exposes circulating blood components to the tissue 
factor-rich lipid-core, inciting thrombosis. Despite the increasing 
appreciation that atherogenesis involves participation of inflamma-
tory pathways within cellular interactions, mediators of local com-
munication between the major cell types within atherosclerotic 
plaques remain incompletely defined. By early appearance, acti-
vated T-cells may act as the orchestrator of atherogenesis. Both 
soluble and contact-dependent mediators from T-cells may be cru-
cial in the development of this prevalent disease. 
Role of Chemokines and Cytokines 
 Several recent studies have addressed the role of chemokines in 
leukocyte accumulation in atherosclerosis, extending our knowl-
edge and understanding of the complex and cell type-specific func-
tions of chemokines in atherosclerosis. Chemokines belong to a 
large group of structurally related and secretable, largely basic, 
chemotactic cytokines, which can be divided into 4 families (CC, 
CXC, CX3C, XC) based on the position of the first 2 cysteine resi-
dues. Chemokines can be located in different vascular cell types, 
eg, endothelial cells (ECs) but also inflammatory cells and can be 
detected within atherosclerotic lesions, where they function as mes-
sengers to direct leukocytes to sites of inflammation but may also 
control homeostasis and other activities of emigrated cells [8,9].  
 The expression of CCL5 can be detected in atherosclerotic 
plaques and in monocyte/macrophages is regulated by the Rel pro-
teins p50 and p65 belonging to the NF-KB family. In addition, the 
Kru¨ppel-like factor 13 (KLF13), originally designated RANTES 
factor of late activated T lymphocytes-1 (RFLAT-1), has been iden-
tified as a new transcription factor regulating the expression of 
CCL5 in T lymphocytes [9,10]. In smooth muscle cells (SMCs), the 
expression of CCL5 has recently been found to be controlled by the 
transcriptional regulator Y-box binding protein-1 (YB-1) [11]. The 
overexpression of YB-1 in arterial SMCs enhanced CCL5 transcrip-
tional activity, CCL5 mRNA and protein expression, and CCL5-
mediated monocyte recruitment. The expression of chemokines in 
inflamed plaque areas is related to different shear stress conditions. 
Whereas low shear stress increases lipid and matrix metalloprotein-
ase (MMP) but decreased vascular SMC and collagen content con-
tributing to atherosclerosis in mice, vortices with oscillatory shear 
stress induced more stable lesions (Cheng C, Tempel D, van Haperen 
R, van der Baan A, Grosveld F, Daemen MJ, Krams R, de Crom R. Athe-
rosclerotic lesion size and vulnerability are determined by patterns 
of fluid shear stress. Circulation 2006; 113: 2744-2753). Whereas 
the expression of CX3CL1 was found in low shear stress regions 
only,blockade of CX3CL1 inhibited plaque growth and resulted in 
striking differences in plaque composition in low shear stress re-
gions of carotid arteries [12]. In the presence of high-shear stress, 
firm adhesion of leukocytes to inflamed ECs was reduced by block-
ing antibodies directed against CX3CL1 or CX3CR1 in Apoe_/_ 
mice, suggesting that this axis is critically involved in leukocyte 
adhesion to inflamed arterial endothelium. Platelets were required 
for CX3CL1-induced leukocyte adhesion at high-shear rates and 
both soluble and membrane-bound CX3CL1 can induce platelet 
degranulation and subsequent surface expression of P-selectin to 
promote direct platelet-leukocyte interactions [13 ]. 
 Lymphotoxin  functions as a proinflammatory cytokine in 
murine atherosclerosis [14]. Either the absence of IL-1 or a reduced 
gene dosage of IL-1 receptor antagonist in the apoE-deficient back-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Inflammatory events in plaque progression.  
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ground suggests an influence of IL-1 in promoting atherogenic cell 
signaling [15,16]. The larger lesions of the IL-1 receptor antagonist-
deficient mice are eriche in macrophages relative to smooth muscle 
cells. The knockout of IFN- in the LDL receptor-deficient back-
ground substantially reduced lesion size in several regions of the 
aorta, with a relative loss of macrophages and smooth muscle cells 
in the early lesions [17]. 
 Nowadays, the cytokines consist of more than 50 secreted fac-
tors involved in intercellular communication, which regulate fun-
damental biological processes including body growth, lactation, 
adiposity, and hematopoiesis [18]. Cytokines are clustered into 
several classes: interleukins [19] have been identified to date), tu-
mor necrosis factors (TNF), interferons (IFN), colony stimulating 
factors (CSF), transforming growth factors (TGF), and chemokines. 
They are especially important for regulating inflammatory and im-
mune responses and have crucial functions in controlling both in-
nate and adaptive immunity. The predominant actors in adaptive 
immunity, helper-T (Th) cells, have been categorized on the basis 
of the pattern of cytokines that they can secrete, resulting in either a 
cell-mediated immune response (Th1) associated with IL-2 and 
IFN- secretion, or a humoral immune response (Th2), associated 
with IL-4, IL-5, IL-10, and IL-13 secretion. 
 According to the classical view of inflammation, cytokines are 
produced by cells of the innate immune system (monocytes, neu-
trophils, NKT cells) in response to microbial infection, toxic rea-
gents, trauma, antibodies, or immune complexes [20]. In the host, 
TLRs and intracellular proteins (NOD1 and NOD2, for “nucleotide-
binding oligomerization domain”) act as sensors of the conserved 
molecular motifs present on a wide range of different microbes, the 
PAMPs. Hence, cytokines are secondary mediators of inflammation 
and not the primary triggers. Once inflammation has been triggered 
and cytokine release is initiated at the onset of atherosclerotic lesion 
development, a number of factors that are found in the atheroscle-
rotic plaque can participate in maintaining and amplifying cytokine 
production. Animal models of atherosclerosis have shown a very 
early role for HSP60 in the development of the disease. Besides 
their role as autoantigens, HSPs can act as an amplifier of the 
cytokine production. Although HSPs are typically regarded as 
intracellular proteins, HSP60 and HSP70 are present in the sera 
of clinically normal individuals [21,22] and enhanced levels of 
circulating HSP60 are associated with early atherosclerosis in 
clinically normal subjects as well as with peripheral vascular 
disease [23]. while TNF- may help in perpetuating sustained lev-
els of proinflammatory cytokines, it does not appear to be a prereq-
uisite for their induction in atherosclerosis. Even though the expres-
sion of proinflammatory cytokines is significantly decreased in 
apoE_/_ mice deficient in TNF- compared with apoE_/_ mice, it 
is not totally abolished. Of importance, the immunoinflammatory 
pathway related to CD40 and its ligand (CD40L) mediates proat-
herogenic biological responses, such as the expression of cytokines, 
chemokines, growth factors, matrix metalloproteinases, and proco-
agulants on EC, SMC, and macrophages,suggesting a major role in 
atherosclerosis. 
 The first evidence that cytokines are expressed in the athero-
sclerotic plaque stems from the observation in the mid 1980s by 
Hansson and co-workers [24] that most of the cells present in the 
plaque express the MHC class II antigen HLA-DR, indicating that 
IFN- must be produced in the vicinity of these cells. This was 
demonstrated later on by the same group [25,26] determined the 
expression profiling of Th1 and Th2 cytokines in advanced human 
atherosclerotic plaques. They found that IL-2 was present in 50% of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Inflammatory cells in atherosclerosis. 
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plaques, and IFN- was detected in some but not all of the IL-2-
positive plaques. In contrast, the expression of IL-4 and IL-5, Th2 
cytokines, and TNF- (lymphotoxin-), expressed by both Th1 and 
Th2 cells, was very scarce, and IL-10 was not detected at all. Sub-
sequent experiments in murine models [26,28] and TGF- [29-34] 
in this setting led to the conclusion that the balance between proin-
flammatory and anti-inflammatory cytokines is decisive for disease 
development and progression. 
 The majority of cytokines stimulates immune cell proliferation 
and differentiation. This group includes IL-1, which activates T 
cells; IL-2, which stimulates proliferation of antigen-activated T 
and B cells; IL-4, IL-5, and IL-6, which stimulate proliferation and 
differentiation of B cells; IFN, which activates macrophages; and 
IL-3, IL-7 and GM-CSF, which stimulate hematopoiesis. Cytokines 
could induce vascular cell growth and migration. Both TNF- and 
IL-6 induce VEGF expression in cultured A431 human epithelial 
carcinoma, and L8 rat skeletal myoblast cell lines [35] IL-1 pro-
motes the growth of rat aorta VSMC via induction of endogenous 
PDGF production, a process that may participate in the abnormal 
proliferation of VSMC that occurs early in atherogenesis [36]. 
Also, IL-1, and inflammatory exudate from zymosan-activated air 
pouches stimulate chemotaxis of SMCs in an extracellular Ca2+-
dependent fashion. These observations suggested that chempattarc-
tants from inflammatory cells such as macrophages and polymor-
phonuclear leukocytes play a role in the migration of SMC into the 
intima during atherogenesis, and that Ca2+ antagonists might be 
useful in reducing SMC migration and in treatment of atherosclero-
sis [37]. 
 Other cytokines such as TNF- may induce apoptosis. TNF- 
initiates apoptosis in many cell types by the recruitment of the DED 
containing protein caspase-8 to the receptor complex following 
association of TRADD and FADD to TNFR-1. This receptor re-
cruitment results in autocatalytic activation of caspase-8. Once 
autocatalytically processed, activated caspase-8 initiates a hierar-
chical series of caspase activation steps culminating in the activa-
tion of effector caspases such as caspase-3 [38]. In EC, transfection 
of the viral caspase-8 inhibitor CrmA inhibits TNF-induced apopto-
sis, suggesting that EC activation of caspase-3 involves upstream 
activation of caspase-8 [39]. 
 Cytokines also promote adhesion of immune cells to ECs and 
cause an increase in vascular permeability. Studies have examined 
the effects of TNF- on the expression of transient receptor poten-
tial channel (TRPC) homologues in human vascular ECs and the 
consequences of TRPC expression on EC permeability. It was 
found that TNF- exposure increased TRPC1 expression in human 
pulmonary artery endothelial cells (HPAEC). Also, thrombin-
induced Ca2+ influx was twofold greater in TNF--stimulated 
HPAEC than in control cells. When TRPC1 was overexpressed in 
human dermal microvascular endothelial cell line (HMEC) using 
TRPC1 cDNA, thrombin-induced depletion of Ca2+ stores in these 
cells caused twofold greater in TNF--stimulated HPAEC than in 
control cells.  
 These findings indicate that TNF- induced expression of 
TRPC1 in ECs is a critical determinant of Ca2+ influx and signal-
ing of increased EC permeability [40]. 
 The various risk factors, represented by particular compounds 
(activators), may cause altered cellular functions in the endothelium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Inflammatory pathways involved in atherosclerotic plaque progression. 
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(e.g. EC-activation or -dysfunction), in invading cells (e.g. inflam-
matory mediator production) or in local vessel wall cells (e.g. in-
flammatory mediators, migration), thereby triggering the innate 
inflammatory process. The cellular components of innate immunol-
ogy include granulocytes, NK-cells and monocytes. Among the 
molecular innate constituentsare innate molecules, such as the toll-
like receptors or innate cytokines. Interleukin-1 (IL-1) and IL-6 are 
among the innate cytokines. Cytokines are potent activators of a 
great number of cellular functions relevant to maintain or commove 
homeostasis of the vessel wall. Within the vessel wall, smooth 
muscle cells can significantly contribute to the cytokine-dependent 
inflammatory network by: a) production of cytokines, b) response 
to cytokines and c) cytokine-mediated interaction with invading 
leukocytes. The cytokines IL-1 and IL-6 are involved in SMC-
leukocyteinteraction. The IL-6 effects are proposed to be mediated 
by trans-signalling. Dysregulated cellular functions resulting from 
dysregulated cytokine production may be the cause of cell accumu-
lation, subsequent LDL accumulation and deposition of extracellu-
lar matrix (ECM). The deposition of ECM, increased accumulation 
of leukocytes and altered levels of inflammatory mediators wall 
may constitute an "innate-immunovascular-memory" resulting in an 
ever-growing response to anew invasion. Thus, vascular smooth 
muscle cell-fostered inflammation, promoted by invading innate 
cells, may be a potent component for development and acceleration 
of atherosclerosis. Plasma levels of cytokines and related proteins, 
such as CRP, have been investigated in cardiovascular patients, 
tissue mRNA expression was analyzed and correlations to vascular 
diseases established. Consistent with these findings the generation 
of cytokine-deficient animals has provided direct evidence for a 
role of cytokines in atherosclerosis. In vitro cell culture experiments 
further support the suggestion that cytokines and other innate 
mechanisms contribute to atherogenesis. Among the initiation path-
ways of atherogenesis are innate mechanisms, such as toll-like-
receptors (TLRs), including the endotoxin receptor TLR4. On the 
other hand, innate cytokines, such as IL-1 or TNF, or even autoim-
mune triggers may activate the cells. Cytokines potently activate 
multiple functions relevant to maintain or spoil homeostasis within 
the vessel wall. Vascular cells, not least smooth muscle cells, can 
actively contribute to the inflammatory cytokine-dependent net-
work in the blood vessel wall by: (i) production of cytokines; (ii) 
response to these potent cell activators; and (iii) cytokine-mediated 
interaction with invading cells, such as monocytes, T-cells, or mast 
cells. Activation of these pathways results in accumulation of cells 
and increased LDL- and ECM-deposition which may serve as an 
'immunovascular memory' resulting in an ever-growing response to 
subsequent invasions. Thus, vascular cells may potently contribute 
to the inflammatory pathways involved in development and accel-
eration of atherosclerosis. 
 Nevertheless the signalling mechanisms via which cytokines 
could affect vascular function and vascular disease need to be fur-
ther examined. Such studies would provide the basis for the use of 
inflammatory cytokines in the diagnosis of vascular disease. 
Role of CD40 and CD40-L  
 Recent reports [41] have helped explain some of these ques-
tions by pointing to a role of contact dependent interaction between 
CD40 and CD40 ligand (CD40L, renamed CD154) as a stimulus for 
atheroma-associated cells. Activated T-lymphocytes within the 
atherosclerotic vessel wall express the CD40 ligand surface mole-
cule, known to play a major role in several immunological path-
ways. In addition to activated T-lymphocytes, functional CD40 and 
CD40L are coexpressed by human vascular endothelial cells, 
smooth muscle cells and human macrophages in vitro as well as in 
situ in human atherosclerotic lesions. Recent studies indicate that 
CD40L activates atheroma-associated cells by promoting the ex-
pression of molecules thought to be involved in atherosclerosis, 
such as adhesion molecules, cytokines, matrix metalloproteinases, 
and tissue factor. Thus, CD40 ligation on these vascular wall cells 
may promote mononuclear cell recruitment, participate in the 
weakening of the plaque and set the stage for thrombosis, mecha-
nisms of crucial importance in the process of atherosclerosis. The 
involvement of the CD40 signaling pathway may play major roles 
during atherogenesis by regulating antigen-specific T-cell responses 
to yield activation instead of tolerance, and the presence of func-
tional CD40L on non-leukocytic cells associated with atheroscle-
rotic lesion indicates a novel T-cell-independent route of inflamma-
tory activation, a now well recognized component of atherogenesis. 
These findings establish a possible crucial role for CD40-CD40L 
interactions in a prevalent human disease. 
 In accordance with the hypothesis that CD40 signaling pro-
motes plaque instability, in vitro studies demonstrated that ligation 
of CD40 on atheroma-associated cell types, namely endothelial 
cells, smooth muscle cells, and macrophages, mediates functions 
considered crucial to the process of atherogenesis, such as the ex-
pression of cytokines, chemokines, growth factors, matrix metallo-
proteinases, and procoagulants. The combination of the broad 
gamut of proatherogenic biological responses triggered by ligation 
of CD40 on endothelial cells, smooth muscle cells, and macro-
phages in vitro and the results of in vivo studies of interruption of 
CD40 signaling suggests a central role for this receptor/ligand dyad 
during atherogenesis, proposing CD40/CD40L interactions as a 
novel potential therapeutic target for this prevalent human disease. 
 CD40 is a cell membrane-spanning protein of '50 kDa that was 
found originally on B lymphocytes. 
 It is responsible for B lymphocyte activation and serves several 
key functions. Engagement of B lymphocyte CD40 by its ligand 
(commonly called CD40L but officially termed CD154) helps pre-
vent induction of apoptosis, induces expression of key costimula-
tory molecules such as B7 for interaction with T lymphocytes, and 
is crucial for B lymphocytes to undergo Ig class switching. The 
display of CD40L on T lymphocytes permits a mutual amplification 
scheme. Key antigen-presenting cells, including macrophages and 
dendritic cells that can activate T lymphocytes, also expressed 
CD40. Engagement of CD40 by T lymphocyte CD40L also served 
to activate these cells to express different functions, such as the 
production of the type 1 cytokines IL-1, IL-12, and tumor necrosis 
factor-a [42]. Interestingly, further analyses showed that nonhema-
topoietic cells including fibroblasts, endothelial cells, smooth mus-
cle cells, and certain epithelial cells expressed CD40 and that its 
display could be markedly up-regulated after exposure to IFN- 
[43-47]. Moreover, CD40 engagement on fibroblasts and endothe-
lial cells induces synthesis of cyclooxygenase-2 and resultant pro-
duction of prostaglandins.  
 CD40-CD40L pathway is a key element in atherosclerosis. 
Endothelial cells, macrophages, and smooth muscle cells from hu-
man atheroma all express high levels of CD40 [48]. Moreover, 
these cells can be activated in vitro with recombinant forms of 
CD40L or with T lymphocyte membranes displaying CD40L to 
express characteristics important in atherosclerosis. 
 These include dramatic up-regulation of connective tissue-
degrading MMP [49]. MMP production induced by CD40 could 
destabilize the fibrous plaque cap and allow rupture with obvious 
consequences. Moreover, studies showed, in two different model 
systems, one with CD40L2y2yApoE2y2 mice and the other with an 
anti-CD40L antibody treatment of low-density lipoprotein receptor-
deficient mice, that initial plaque lesions were smaller and were of 
a more stable composition [49]. A study in humans has shown re-
cently that patients with unstable angina have particularly high 
blood levels of soluble and membranebound forms of CD40L [50]. 
These observations suggest that chronic provocation by CD40L and 
activation of CD40- L bearing cells, especially in the plaque micro-
environment, could lead to plaque destabilization and rupture.  
 The interaction of CD40 with CD40L figures prominently in 
both humoral and cell-mediated immune responses. CD40L-
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positive T cells accumulate in atheroma, and, by virtue of their 
early appearance, persistence and localization at sites of lesion 
growth and complication, activated T cells may coordinate impor-
tant aspects of atherogenesis. Interruption of CD40L-CD40 signal-
ling by administration of an anti-CD40L antibody limits experimen-
tal autoimmune diseases such as collagen-induced arthritis, lupus 
nephritis, acute or chronic graft-versus-host disease, multiple scle-
rosis and thyroiditis. Ligation of CD40 on atheroma-associated cells 
in vitro activates functions related to atherogenesis, including in-
duction of proinflammatory cytokines, matrix metalloproteinases, 
adhesion molecules and tissue factor. However, the role of CD40 
signalling in atherogenesis in vivo remains unknown. Shonbeck et 
al. [51] reported that anti-CD40L antibody treatment of randomly 
assigned low-density lipoprotein receptor-deficient mice during the 
second half of a 26-week regimen of high-cholesterol diet did not 
regress, but did significantly reduce further evolution of established 
atherosclerotic lesions within the aortic arch and particularly the 
thoracic and abdominal aorta, as compared with control treatment 
(application of rat-IgG or saline; 13 weeks, continued high-
cholesterol diet). In addition to limiting lesion progression, anti-
CD40L treatment changed the composition of atheroma in manners 
thought to favor plaque stability, e.g, reduced relative content of 
macrophages and lipid, as well as increased relative content of 
smooth muscle cells and collagen. These data implicate 
CD40/CD40L as crucial mediators not only in the initial events of 
atherogenesis but also during the evolution of established atheroma.  
 Mach et al. [52] determined whether interruption of CD40 sig-
nalling influences atherogenesis in vivo in hyperlipidaemic mice. 
Treatment with antibody against mouse CD40L limited atheroscle-
rosis in mice lacking the receptor for low-density lipoprotein that 
had been fed a high-cholesterol diet for 12 weeks. This antibody 
reduces the size of aortic atherosclerotic lesions by 59% and their 
lipid content by 79%. Furthermore, atheroma of mice treated with 
anti-CD40L antibody contained significantly fewer macrophages 
(64%) and T lymphocytes (70%), and exhibited decreased expres-
sion of vascular cell adhesion molecule-1. These data support the 
involvement of inflammatory pathways in atherosclerosis and indi-
cate a role for CD40 signalling during atherogenesis in hyperlipi-
daemic mice. 
Role of T and B Cells 
 Atherosclerosis starts with an innate immune response involv-
ing the recruitment and activation of monocytes   macrophages that 
respond to an excessive accumulation of modified lipids within the 
arterial wall, followed by an adaptive immune response involving 
antigen-specific T lymphocytes. Effector T cells recognize modi-
fied auto-antigens such as oxidized LDL and heat shock proteins 
(i.e. HSP-60) that are presented by antigen-presenting cells such as 
macrophages or dendritic cells [53]. The accumulation of inflam-
matory cells within the arterial wall leads to local production of 
chemokines, interleukins and proteases that enhance the influx of 
monocytes and lymphocytes, thereby promoting the progression of 
atherosclerotic lesions [54]. T-cells may be divided into CD4 + and 
CD8+ subclasses. 
 The majority of T-cells in atherosclerotic plaques are CD4+ 
cells, although smaller numbers of CD8+ cells have been detected. 
CD4+ cells recognize antigen loaded on MHC class II molecules of 
the antigen-presenting cell, whereas CD8+ cells recognize antigens 
presented in the context of MHC class I molecules. Among the 
CD4+ cells are several subgroups, three of which have been inves-
tigated in murine atherosclerosis. These subgroups are distin-
guished by the complement of cytokines they produce. Th1 cells 
mainly secrete proinflammatory cytokines such as IFN- which 
activates macrophages and facilitates the production of antibodies 
of the IgG2a class by B-cells. T-helper 1 (Th1) cells do not secrete 
IL-4 or IL-5. Th2 cells, on the other hand, secrete IL-4 and IL-5 but 
not IFN-. These cells provide help for the synthesis of other anti-
body classes. The Th2 cytokines may be anti-inflammatory.There is 
cross-regulation among these two subsets of T-cells, so that each 
tends to inhibit the other. IFN- inhibits Th2 cells and IL-4 inhibits 
Th1 cell cytokine secretion. Also,IL-10 inhibits the Th1 pathway, 
whereas IL-12 reduces the Th2 responses [55]. A third special sub-
set of T-cells are the natural killer T cells (NK-T cells), which bear 
some of the same markers as NK cells, but unlike the latter they 
express rearranged cell surface TCRs of limited diversity. They 
mainly recognize lipid antigen in the context of the MHC-like com-
pound CD1. There are other T-cell subsets that have been less stud-
ied in atherosclerosis (e.g, T-regulatory cells, Th3 cells, etc.). 
 Some authors reported that Th1-driven responses, characterized 
by c-interferon (IFN-c) production are detrimental to the atheroscle-
rotic process [56,57] The role of the Th2 pathway in the develop-
ment of atherosclerosis remains controversial depending on the 
stage and   or site of the lesion, as well as on the experimental 
model [58] 
 IFN--producing TH1 CD4+ T-cells with  T-cell receptors 
constitute the majority of T lymphocytes present in human 135 and 
experimental 136 atherosclerotic lesions [59] T-cells enter lesions 
in response to the chemokines inducible protein-10 (IP-10), 
monokine induced by IFN- (MIG), and IFN-inducible T-cell -
chemoattractant (I-TAC), which bind CXCR3, highly expressed by 
T lymphocytes in the plaque 137. CD4+ T-cells undergo oligo-
clonal expansion within lesions, suggesting the occurrence of anti-
gen-driven T-cell proliferation 138. Indeed, CD4+ T-cell clones in 
plaques recognize oxLDL 139 and hsp60 [60]. Experimental evi-
dence supports an important role for CD4+ T-cells in atherosclero-
sis. 
 Immunodeficient RAG (recombinase activating gene)-deficient 
[61] or DNA-PK (DNAdependent protein kinase)-knockout [62] 
atherosclerosis-prone mice have no lymphocytes and reduced le-
sions compared to immunocompetent atherosclerosis-prone mice. 
Adoptive transfer of CD4+ T-cells into immunodeficient animals, 
however, greatly increases lesion size in parallel to increased T-cell 
recruitment and MHC-II expression in plaques In mice, decreased 
Treg numbers 189 or Treg function secondary to absence of ICOS 
128 leads to increased lesional CD4+ T cells and macrophage num-
bers as well as amplified expression of the pro-inflammatory cyto-
kines IFN- and TNF-. Moreover, patients with acute coronary 
syndromes have reduced circulating Treg numbers and suppressive 
function [63]. Conversely, the adoptive transfer of Tregs [64] or 
Treg-induction secondary to measles virus nucleoprotein vaccina-
tion[65] inhibits macrophage and T-cell accumulation within le-
sions. In addition, leptin deficiency in atherosclerosis-prone mice 
reduces atherosclerotic lesion formation, in association with dimin-
ished Th1 responses in addition to a marked increase in the number 
and suppressive function of Tregs. 
 B-cells are the other major group of circulating lymphocytes. 
They recognize antigen via the B-cell antigen receptor, in which 
cell surface IgM plays a central role. Like T-cells, B-cells, through 
these receptors, express unique specificity derived from the rear-
rangement of immunoglobulin genes, a process that is also RAG 
dependent. Mature B-cells, designated as plasma cells, secrete spe-
cific antibodies. The production of antibodies to protein antigen 
requires T-cell help. The interaction between T-cells and B-cells is 
facilitated by CD40 ligand (CD40L) expressed on T-cells and 
CD40 on B-cells [66]. 
 Stromelysin-3 is an unusual matrix metalloproteinase, being 
released in the active rather than zymogen form and having a dis-
tinct substrate specificity, targeting serine proteinase inhibitors 
(serpins), which regulate cellular functions involved in atheroscle-
rosis. Schönbeck et al. [67] reported that human atherosclerotic 
plaques (n = 7) express stromelysin-3 in situ, whereas fatty streaks 
(n = 5) and normal arterial specimens (n = 5) contain little or no 
stromelysin-3. Stromelysin-3 mRNA and protein colocalized with 
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endothelial cells, smooth muscle cells, and macrophages within the 
lesion. In vitro, usual inducers of matrix metalloproteinases such as 
interleukin-1, interferon-gamma, or tumor necrosis factor alpha did 
not augment stromelysin-3 in vascular wall cells. However, T cell-
derived as well as recombinant CD40 ligand (CD40L, CD154), an 
inflammatory mediator recently localized in atheroma, induced de 
novo synthesis of stromelysin-3. In addition, stromelysin-3 mRNA 
and protein colocalized with CD40L and CD40 within atheroma. In 
accordance with the in situ and in vitro data obtained with human 
material, interruption of the CD40-CD40L signaling pathway in 
low density lipoprotein receptor-deficient hyperlipidemic mice 
substantially decreased expression of the enzyme within atheroscle-
rotic plaques. These observations establish the expression of the 
unusual matrix metalloproteinase stromelysin-3 in human athero-
sclerotic lesions and implicate CD40-CD40L signaling in its regula-
tion, thus providing a possible new pathway that triggers complica-
tions within atherosclerotic lesions, 
 Furthermore, Häkkinen T et al. [68] studied the expression 
profile of CD40-CD40L in different types of human atherosclerotic 
lesions using double immunostaining techniques with cell type-
specific antibodies. Normal human intima did not contain CD40 or 
CD40L immunoreactivity. From type-II lesions (fatty streaks) to 
advanced type-VI lesions (complicated plaques), colocalization of 
CD40 and CD40L was observed in T cells (CD3+ cells), macro-
phages (CD68+ cells), and smooth muscle cells (HHF35+ cells). 
No correlation was found between the lesion type and CD40-
CD40L expression. Positive lesions had dense infiltrations of 
macrophages and macrophage-derived foam cells together with T 
cells. The most intensive immunoreactivity for the CD40 receptor 
and its ligand CD40L was found in macrophage- and T-cell-rich 
pockets, where both cell types were in close contact with each 
other. The majority of macrophages, and especially those of macro-
phage-derived foam cells, were positive for both CD40 and CD40L. 
A small subset of the lesion macrophage population (10-20%) con-
sisted of cells positive only for either CD40 or CD40L, suggesting 
the presence of a subpopulation of macrophages more active in 
inflammatory processes than in lipid uptake. Intimal smooth muscle 
cells in and around the macrophage-rich areas as well as some of 
the medial smooth muscle cells near the lesions stained positive for 
CD40 and CD40L. Moderate to faint expression of these proteins 
was also found in endothelium. In addition, CD40-CD40L immuno-
reactivity colocalized with epitopes characteristic of oxidized low-
density lipoprotein, scavenger receptor class A, and CD16 (Fc 
gammaRIII), thus suggesting the involvement of CD40-CD40L and 
these pathogenetic mediators in foam cell formation, progression of 
atherosclerotic lesions, and differentiation of immunologically ac-
tive subsets of macrophages. These results support the hypothesis 
that CD40-CD40L interaction is involved in atherogenesis and that 
it might provide a target for future therapeutic interventions. 
 Furthermore, In elderly subjects and in patients with chronic 
inflammatory diseases, there is an increased subset of monocytes 
with a CD14(+)CD16(+) phenotype, whose origin and functional 
relevance has not been well characterized. Merino et al. [69] deter-
mined whether prolonged survival of human CD14(++)CD16(-) 
monocytes promotes the emergence of senescent cells, and we ana-
lyzed their molecular phenotypic and functional characteristics. We 
used an in vitro model to prolong the life span of healthy mono-
cytes. We determined cell senescence, intracellular cytokine ex-
pression, ability to interact with endothelial cells, and APC activity. 
CD14(+)CD16(+) monocytes were senescent cells with shortened 
telomeres (215 ± 37 relative telomere length) versus CD14(++) 
CD16(-) cells (339 ± 44 relative telomere length; p < 0.05) and 
increased expression of -galactosidase (86.4 ± 16.4% versus 10.3 
± 7.5%, respectively; p = 0.002). CD14(+)CD16(+) monocytes 
exhibited features of activated cells that included expression of 
CD209, release of cytokines in response to low-intensity stimulus, 
and increased capacity to sustain lymphocyte proliferation. Finally, 
compared with CD14(++)CD16(-) cells, CD14(+)CD16(+) mono-
cytes showed elevated expression of chemokine receptors and in-
creased adhesion to endothelial cells (19.6 ± 8.1% versus 5.3 ± 
4.1%; p = 0.033). These data indicated that the senescent 
CD14(+)CD16(+) monocytes are activated cells, with increased 
inflammatory activity and ability to interact with endothelial cells. 
Therefore, accumulation of senescent monocytes may explain, in 
part, the development of chronic inflammation and atherosclerosis 
in elderly subjects and in patients with chronic inflammatory dis-
eases. 
Role of Monocytes 
 Monocytes circulate in the blood, bone marrow and spleen of 
mice in homeostasis. These cells are short-lived, and do not prolif-
erate in the blood [70] their functions under homeostatic conditions 
remain unresolved. They might be involved in scavenging dead 
cells and toxic molecules, and/or have a potential role in the re-
newal of ‘resident’ tissue macrophages and DCs. During inflamma-
tion, blood monocytes migrate from blood to lymphoid and non-
lymphoid tissues in response to tissue-derived signals caused, for 
example, by infection or tissue damage [71]. They phagocytose 
other cells and toxic molecules (such as oxidized LDL [oxLDL]), 
produce inflammatory cytokines, and can differentiate into inflam-
matory DCs, macrophages or foam cells [72,73].  
 During the pathogenesis of atherosclerosis, blood monocytes 
are recruited into intima and subintima [74]. Through their scaven-
ger receptors, these cells can take up oxLDL and other lipids, con-
sequently, it is thought that, when they encounter fatty deposits, 
they are induced to undergo activation and accumulate in the form-
ing lesion. At an early stage of the process, monocytes differentiate 
into foam cells to form early plaques, termed fatty streaks, in the 
intima [75]. Interestingly, this process occurs in atherosclerosis-
prone areas of the arterial tree, such as artery branches, and is very 
likely to involve cellular responses to changes in fluid dynamics. 
 Although monocytes are recruited into the plaque during its 
growth, they might also emigrate from the plaque, at least under 
some experimental conditions that are associated with a decrease in 
plaque size and, consequently, regression of atherosclerosis [76,77]. 
Monocytes might enter lymphatic vessels and then travel to the 
draining lymph node, or they might migrate across the arterial en-
dothelium towards the artery lumen to directly enter the circulating 
bloodstream [78]. 
 Monocytes and macrophages were the first inflammatory cells 
to be associated with atherosclerosis. Gerrity et al. [79] identified 
monocytes as the main cellular component of atherosclerotic 
plaques in porcine specimens. Monocytes are already present in 
fatty streaks, the earliest visible lesion in human and experimental 
sclerosis [80]. Depletion of monocytes from the circulation using 
clodronate (dichloromethylene bisphosphonate) was associated with 
considerably reduced plaque formation in rabbits, suggesting the 
importance of monocytes in atherosclerosis [81] showed that 
CD11b+ cells are critical to atherogenesis, but that, once formed, 
the plaque mass was not reduced by depleting CD11b+ cells. As 
CD11b is broadly expressed, and because clodronate also kills sev-
eral macrophages subsets, these experiments do not formally prove 
the role(s) of monocytes in atherosclerosis. In addition, if different 
monocyte subsets have opposing functions, depleting all monocytes 
will not be sufficient to understand their roles. 
 Activation of monocytes and differentiation into lipid-laden 
macrophages are fundamental events in the formation of atheroscle-
rotic lesions. Marginalization of monocytes along the endothelium 
and transmigration into the intimal spaces appears to depend on the 
local presence of high amounts of oxidized lowdensity lipoprotein 
cholesterol and are mediated by adhesion molecules (vascular cell 
adhesion molecule, intercellular adhesion molecule, and selectin) 
expressed by the endothelium. [82,83]. Previous studies have found 
elevated levels of circulating adhesion molecules in subjects with 
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carotid atherosclerosis [84,85]. In a recent community-based study, 
monocyte count in blood was found to be a better cross-sectional 
marker of plaque presence than IL-6, high-sensitive C-reactive 
protein, fibrinogen, and white blood cells [86]. 
 On this basis monocytes and lymphocytes, but not neutrophils, 
are the main cellular components of the circulation in generating 
atherosclerotic lesions. Monocyte count may therefore be a better 
and more specific marker than WCC of the inflammatory activity in 
atherosclerosis, Microparticles are membrane vesicles with proco-
agulant and proinflammatory properties released during cell activa-
tion or apoptosis. Microparticles from monocytes have been impli-
cated in atherosclerosis and vascular inflammation, but their direct 
effects on endothelial cells are not completely elucidated. Mas-
tronardi et al. [87] designed a study to dissect the signaling path-
ways of monocytic microparticles in endothelial cells with respect 
to both NO pathway and reactive oxygen species. Microparticles 
were produced by treatment of human monocytic cell line THP-1 
with the apoptotic agent VP-16. Human endothelial cells were 
treated with monocytic microparticles and authors studied their 
effects on nitrosative and oxidative stresses. Incubation of human 
endothelial cells with microparticles enhanced the production of 
NO without affecting superoxide anions generation. Microparticles 
did not affect endothelial NO synthase expression and its phos-
phorylation. Interestingly, microparticles decreased caveolin-1 ex-
pression and increased its phosphorylation. Inhibition of PI-3-
kinase or MEK1/2 reversed the effects of microparticles on caveo-
lin-1 expression but not its phosphorylation. Moreover, microparti-
cles increased nitration of several proteins, reflecting peroxynitrite 
production, which was prevented by blockade of PI-3-kinase path-
way. In summary, monocyte microparticles active multiple path-
ways related to nitrosative stress in endothelial cells including both 
PI-3-kinase and ERK1/2 in the regulation of caveolin-1 expression. 
These data underscore the pleiotropic effect of microparticles on 
endothelial cells and suggest that they probably play a critical role 
on vascular function.  
 Circulating monocytes can be divided into functionally distinct 
subpopulations according to their surface expression of CD14 and 
CD16. Monocytes with high-level expression of both antigens 
(CD14(++)CD16(+), Mo2 cells) are associated with cardiovascular 
morbidity and mortality in hemodialysis patients. These cells ex-
press angiotensin converting enzyme (ACE) on their surface. They 
are involved in the association of chronic inflammation and cardio-
vascular disease in kidney patients. Cardiovascular morbidity re-
sults from atherosclerosis (plaque-forming, vessel occluding dis-
ease) and arteriosclerosis (loss of arterial dampening function).  
 In a study by Ulrich et al. [88] 60 chronic hemodialysis patients 
were screened for atherosclerosis by carotid artery ultrasound, for 
arteriosclerosis by pulse pressure measurement, and for ACE ex-
pression on Mo2 cells by flow cytometry. Authors reported that 
ACE expression on Mo2 monocytes was significantly higher in 
patients with severe compared with those with little or no carotid 
atherosclerosis. Mo2 ACE correlated with a score to semiquantify 
atherosclerosis and remained a significant predictor of carotid 
plaques in multivariate analysis including the other univariately 
associated variables of age, hemoglobin A1c, and albumin. Mo2 
ACE was not related to pulse pressure. On this basis ACE expres-
sion on Mo2, although being a known predictor of mortality and 
cardiovascular disease in end-stage renal disease patients, may act 
via enhancement of atherosclerosis rather than arteriosclerosis. 
 Markers of monocyte activation play a critical role in athero-
sclerosis, but little is known about the genetic influences on cellular 
levels. Bielinski et al. [89] investigated the influence of genetic 
variants in monocyte differentiation antigen (CD14), toll-like recep-
tor-4 (TLR4), toll-like receptor-2 (TLR2), and myeloperoxidase 
(MPO) on monocyte surface receptor levels. The study sample 
consisted of 1,817 members of a biracial cohort of adults from the 
Atherosclerosis Risk in Communities Carotid MRI Study. Mono-
cyte receptors were measured using flow cytometry on fasting 
whole blood samples. TLR2 rs1816702 genotype was significantly 
associated with CD14+/TLR2+ percent of positive cells (%) and 
median fluorescence intensity (MFI) in whites but not in blacks 
(p < 0.001). Specifically, the presence of the minor T-allele was 
associated with increased receptor levels. In blacks, TLR4 
rs5030719 was significantly associated with CD14+/TLR4+ mono-
cytes (MFI) with mean ± SE intensities of 16.7 ± 0.05 and 
16.0 ± 0.14 for GG and GT/TT genotypes, respectively (p < 0.001). 
Variants in TLR2 and TLR4 were associated with monocyte recep-
tor levels of TLR2 and TLR4, respectively, in a biracial cohort of 
adults. This is the first study to look at associations between vari-
ants in the toll-like receptor family and toll-like receptor levels on 
monocytes. Patients with systemic lupus erythematosus (SLE) have 
a high risk of developing cardiovascular disease; however, the 
mechanisms involved in the early onset of atherosclerosis in these 
patients are not clear. Scavenger receptors, CD36 and CD163 are 
expressed by mononuclear phagocytes and participate in the bind-
ing and uptake of oxidized low-density lipoproteins (Ox-LDL), 
contributing to foam-cells formation and atherosclerosis develop-
ment. Recently some authors [90] evaluated CD36(+) and 
CD163(+) expression and Ox-LDL removal by monocytes from 
SLE and atherosclerotic patients, compared to similar age-range 
healthy controls. Healthy controls, SLE, and atherosclerotic patients 
were evaluated for carotid intima media thickness (CIMT), lipid 
profile, and native LDL (N-LDL) and Ox-LDL binding/endo-
cytosis. SLE patients presented decreased high-density lipoproteins 
(HDL) and increased Triglyceride levels, and half of the SLE pa-
tients had increased CIMT, compared to their healthy controls 
(HC(SLE)). The number of CD14(+)CD163(+) cells was increased 
in atherosclerosis healthy controls (HC(Atheros)) compared to 
HC(SLE), but there were no differences between SLE or athero-
sclerotic patients and their respective healthy controls. Clearance 
assays revealed a similar capacity to bind/endocytose Ox-LDL by 
monocytes from SLE patients and HC(SLE), and an increased bind-
ing and endocytosis of Ox-LDL by monocytes from atherosclerotic 
patients, compared to HC(Atheros). The decreased CD36 and 
CD163 expression observed in atherosclerotic and SLE patients, 
respectively, suggest that these inflammatory conditions modulate 
these receptors differentially. The increased CIMT observed in SLE 
patients cannot be explained by Ox-LDL binding/endocytosis, 
which was comparable to their controls. 
 Membrane-shed submicron microparticles (MPs) released fol-
lowing cell activation or apoptosis accumulate in atherosclerotic 
plaques, where they stimulate endothelial proliferation and neoves-
sel formation. A study by Rautou et al. [91] was to assess whether 
or not MPs isolated from human atherosclerotic plaques contribute 
to increased endothelial adhesion molecules expression and mono-
cyte recruitment. Human umbilical vein and coronary artery endo-
thelial cells were exposed to MPs isolated from endarterectomy 
specimens (n=62) and characterized by externalized phosphatidyl-
serine. Endothelial exposure to plaque, but not circulating, MPs 
increased ICAM-1 levels in a concentration-dependant manner 
(3.4-fold increase) without affecting ICAM-1 mRNA levels. Plaque 
MPs harbored ICAM-1 and transferred this adhesion molecule to 
endothelial cell membrane in a phosphatidylserine-dependent man-
ner. MP-borne ICAM-1 was functionally integrated into cell mem-
brane as demonstrated by the increased ERK1/2 phosphorylation 
following ICAM-1 ligation. Plaque MPs stimulated endothelial 
monocyte adhesion both in culture and in isolated perfused mouse 
carotid. This effect was also observed under flow condition and was 
prevented by anti-LFA-1 and anti-ICAM-1 neutralizing antibodies. 
MPs isolated from symptomatic plaques were more potent in stimu-
lating monocyte adhesion than MPs from asymptomatic patients. 
Plaque MPs did not affect the release of interleukin-6, interleukin-8, 
or MCP-1, nor the expression of VCAM-1 and E-selectin. Results 
of this study demonstrate that MPs isolated from human atheroscle-
rotic plaques transfer ICAM-1 to endothelial cells to recruit in-
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flammatory cells and suggest that plaque MPs promote atheroscle-
rotic plaque progression. 
 So, the role of monocyte in atherosclerosis is well demonstred 
and since affinity of the monocyte/macrophage integrin MAC-1 
(CD11b/CD18) is upregulated in inflammation, it’s possible to 
generate a contrast agent targeting CD11b (CD11b-SPIOs) for im-
proved macrophage detection in plaques. In a study by Von Zur 
Mohlen et al. [92] CD11b-SPIOs and non-targeted SPIOs (control-
SPIOs) were incubated in vitro with human monocytes/macro-
phages. As quantified by SPIO-induced MRI signal extinction, 
intracellular iron-content was significantly higher in monoytes/ 
macrophages incubated with CD11b-SPIO than with control-SPIO 
in vitro (p < 0.05), suggesting an improved uptake of CD11b-SPIOs 
into monocytes. Therefore, the aortic arch (AA) and vessel 
branches of ApoE(-/-)-knockout mice on a Western-type diet were 
imaged before and 48 h after contrast agent injection of either 
CD11b-SPIOs or control-SPIOs, using a 9.4 T animal MRI system. 
The SPIO-induced change in the MRI signal was quantified, as well 
as the macrophage-content by anti-CD68 immunhistochemistry and 
the iron-content by Prussian-blue staining. However, SPIO-induced 
signal extinction in in vivo-MRI was similar in CD11b-SPIO and 
control-SPIO-injected animals, with a non-significant trend towards 
an improved uptake of CD11b-SPIOs in the subclavian artery and 
subsections of the AA. These data correlated well with the results 
obtained by histology. Although in vitro MRI-data indicated an 
increased uptake of targeted CD11b-SPIOs in monocytes/macro-
phages, in vivo mouse data do not allow improved atherosclerotic 
plaque detection compared WITH non-targeted SPIOs. Therefore, 
CD11b-targeted MRI contrast labelling of monocytes/macrophages 
does not seem to be a successful strategy in stable atherosclerotic 
plaques such as found in the ApoE(-/-)-knockout-model. However, 
the impressive correlation between MRI and histology data encour-
ages further development of inflammation- and plaque-specific 
contrast agents for vulnerable plaque imaging. 
Role of Macrophages 
 Macrophages are innate immune effectors, i.e. they are acti-
vated without antigenic specificity. Macrophages are recruited and 
activated by many signals and have an impressive armamentarium 
of molecules to promote tissue damage. Macrophages play impor-
tant roles in the progression of atherosclerosis by exhibiting unique 
characteristics under the various stimuli, evolving the plaque insta-
bility, thrombus formation and remodeling. Macrophage recruit-
ment by abnormal endothelium over developing atherosclerotic 
plaques, is aided by endothelial expression of adhesion molecules 
(ICAM-1, VCAM, ELAM) [93]. Use of knockout mice has impli-
cated the chemoattractant cytokine (chemokine) MCP-1 in attract-
ing macrophage recruitment in atherosclerosis. Macrophage-
activation stimuli associated with atherosclerotic risk factors in-
clude oxidised low density lipoprotein (oxLDL, "bad cholesterol"), 
advanced glycosylation end products (AGEs) of diabetes, angio-
tensin II and endothelin. Substantial work has clarified macrophage 
activation by OxLDL via macrophage scavenger receptors (MSRs), 
especially MSRA and CD36. Activated macrophages express effec-
tor molecules that kill cells and degrade extracellular matrix. These 
include Fas-L and nitric oxide (NO). Macrophage NO is derived 
from the high output inducible nitric oxide synthase (iNOS) path-
way and upregulates vascular smooth muscle (VSMC) cell surface 
Fas, priming them for apoptosis. Activated macrophages express 
surface Fas-L, similar to cytotoxic T-lymphocytes and natural killer 
cells. Since VSMCs promote plaque stability, VSMC apoptosis 
may promote plaque rupture. Macrophages express multiple metal-
loproteinases (e.g. stromelysin) and serine proteases (e.g. 
urokinase) that degrade the extracellular matrix, weakening the 
plaque and making it rupture prone. Macrophages secrete numerous 
other effectors including reactive oxygen species, eicosanoids, tu-
mour necrosis factor alpha and interleukin-1. Macrophage-derived 
transforming growth factor beta promotes fibrosis. Existing cardio-
vascular treatments including angiotensin II receptor antagonists 
and angiotensin converting enzyme inhibitors, aspirin, cholesterol 
reduction agents especially statins may inhibit macrophages. The 
interaction of NO-donors with macrophages and apoptosis is com-
plex and bifunctional [94].  
 A recent study [94] have shown the molecules-associated with 
metabolism, such as sirtuin-1 and peroxisome proliferator -
activated receptor gamma in macrophages, appear to be involved to 
modulate the atherosclerotic process.  
 The peroxisome-proliferator-activated receptor gamma is a 
member of the nuclear receptor superfamily that functions as a key 
transcriptional regulator of cell differentiation and lipid metabo-
lism. Oxidized low-density lipoprotein, which plays a central role in 
lesion development, can activate peroxisome-proliferator-activated 
receptor gamma by providing the cell with oxidized fatty acid 
ligands of the receptor. The elucidation of a peroxisome-proli-
ferator-activated receptor gamma signalling pathway in macro-
phages provides a mechanism by which oxidized lipids may di-
rectly regulate gene expression in the context of the atherosclerotic 
lesions. A number of potential target genes for peroxisome-
proliferator-activated receptor gamma in these cells have been iden-
tified. Some, such as the type B scavenger receptor CD36 are in-
duced by peroxisome-proliferator-activated receptor gamma 
ligands, whereas others, such as scavenger receptor type A, induc-
ible nitric oxide synthetase and certain cytokines, are repressed. 
Given the widespread clinical use of thiazolidinediones, it is impor-
tant to consider the influence of these drugs on the risk of athero-
sclerosis. The net effect of peroxisome-proliferator-activated recep-
tor gamma ligands on the atherogenic process is likely to reflect a 
balance between local effects in the artery wall and systemic effects 
on lipid metabolism. 
 Macrophages work coordinately with other immune cells like 
mast cells. Macrophages are central to the initiation and progression 
of atherosclerosis and thus can be very appropriate targets for ther-
apy. Cell adhesion molecules mediating monocytes recruitment to 
the endothelium are attractive therapy targets and their inhibitors 
are in clinical trials. Macrophage scavenger receptors like SR-A 
and CD-36 mediate foam cell formation by facilitating the uptake 
of modified lipids. Peroxisome proliferator-activated receptors 
(PPAR), liver X receptor (LXR)-mediated signaling, mitogen-
activated protein kinase (MAPK) induced phosphorylation events 
seem to play an important role in this phenomenon. Proteins affect-
ing macrophage cholesterol metabolism and transport, including 
ATP-binding cassette (ABC) A1, ABCG1, acyl-CoA: cholesterol 
acyltransferase (ACAT), apolipoprotein A-1 (ApoA-1), neutral 
cholesteryl ester hydrolase (NCEH) also regulate foam cell forma-
tion and are being developed as therapeutic targets by many phar-
maceutical companies. Macrophage proliferation and apoptosis are 
important events controlling inflammatory response, plaque vulner-
ability, and destabilization [95]. Free cholesterol (FC) activates the 
macrophage endoplasmic reticulum (ER) stress pathway and apop-
tosis. Free radicals and nitric oxide also modulate macrophage foam 
cell formation and apoptosis. Various antioxidants like AGI-1067 
and BO-653 are in clinical trials for atherosclerosis treatment. 
Macrophage matrix metalloproteinase's (MMP's) play a significant 
role in weakening and rupture of plaques. Efforts are on to develop 
isoform specific MMP inhibitor. CD-14, MMP-3, ABCA1, Toll-
like receptor-4 (TLR-4), lectin-like oxidized low-density lipopro-
tein receptor-1 (LOX-1), arachidonate lipoxygenase-15 (ALOX-
15), and Connexin37 polymorphisms and macrophage dysfunction 
signify their importance in atherosclerosis. Deciphering the role of 
macrophages in regulating dyslipidemia and inflammation during 
atherosclerosis is important for developing them as therapeutic 
targets. 
 The macrophage plays a diverse array of roles in atherogenesis 
and lipoprotein metabolism. The macrophage functions as a scav-
enger cell, an immune mediator cell, and as a source of chemotactic 
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molecules and cytokines [96]. Chemokines have been implicated in 
promoting migration of monocytes into the arterial intima. Mono-
cyte chemoattractant protein-1 (MCP-1) attracts monocytes bearing 
the chemokine receptor CCR-2. Macrophage expression of cy-
clooxygenase-2, a key enzyme in inflammation, promotes athero-
sclerotic lesion formation in low-density lipoprotein receptor 
(LDLR)-deficient mice. In the arterial intima, monocytes differenti-
ate into macrophages, which accumulate cholesterol esters to form 
lipid-laden foam cells. Foam cell formation can be viewed as an 
imbalance in cholesterol homeostasis. The uptake of atherogenic 
lipoproteins is mediated by scavenger receptors, including SR-A 
and CD36. In the macrophage, ACAT-1 is responsible for esterify-
ing free cholesterol with fatty acids to form cholesterol esters. Sur-
prisingly, deficiency of macrophage ACAT-1 promotes atheroscle-
rosis in LDLR-deficient mice. A number of proteins have been 
implicated in the process of promoting the efflux of free cholesterol 
from the macrophage, including apoE, ABCA1, and SRB-1. 
Macrophage-derived foam cells express the adipocyte fatty acid-
binding protein (FABP), aP2, a cytoplasmic FABP that plays an 
important role in regulating systemic insulin resistance in the set-
ting of obesity. ApoE-deficient mice null for macrophage aP2 ex-
pression develop significantly less atherosclerosis than controls 
wild type for macrophage aP2 expression. These results demon-
strate a significant role for macrophage aP2 in the formation of 
atherosclerotic lesions independent of its role in systemic glucose 
and lipid metabolism. Furthermore, macrophages deficient in aP2 
display alterations in inflammatory cytokine production. Through 
its distinct actions in adipocytes and macrophages, aP2 links fea-
tures of the metabolic syndrome including insulin resistance, obe-
sity, inflammation, and atherosclerosis. 
 Mechanisms responsible for macrophage recruitment to and 
retention in the vessel wall are poorly understood; however, genetic 
data in humans and/or mouse have implicated the macrophage 
chemokine receptors CXCR2, CCR2, and CX3CR1 and their re-
spective ligands CXCL8, CCL2, and CX3CL1, which may be in-
duced in resident vascular cells by oxidized LDL and other factors 
[97, 98].  
 CX3CR1 is particularly noteworthy because both cx3cr1+/_ 
and cx3cr1_/_ mice have been reported to have reduced susceptibil-
ity to atherosclerosis [99-101] and because human subjects het-
erozygous for the CX3CR1 M280 allele, which encodes a defective 
receptor, have reduced risk of atherosclerotic cardiovascular disease 
[102.] CX3CR1 is an unusual chemokine receptor because, in addi-
tion to mediating leukocyte migration toward soluble CX3CL1, it is 
able to mediate direct adhesion of leukocytes to endothelial cells 
expressing a tethered form of CX3CL1 under both static and 
physiological flow condition. 
 Barlic et al. [103] showed that oxidized linoleic acid metabo-
lites, which are components of oxidized LDL found in large 
amounts in atherosclerotic plaque, were able to specifically induce 
differentiation of human monocytes to macrophages with decreased 
expression of CCR2, confirming a previous report, and increased 
expression of CX3CR1. These macrophages acquired the ability to 
adhere to coronary artery smooth muscle cells. The adhesion was 
mediated directly and predominantly by CX3CR1. 
 Reciprocal effects of these lipids on CCR2 and CX3CR1 ex-
pression were mediated by the nuclear receptor peroxisome prolif-
erator-activated receptor (PPAR) , and targeting the PPAR gene 
with sRNAi dramatically reduced macrophage adhesion to coronary 
artery smooth muscle cells. 
 These data suggest that in atherogenesis oxidized lipid-driven 
activation of macrophage PPAR_ in the intima may result in a 
proadhesive chemokine receptor switch-CCR2 off, CX3CR1 on-
causing cessation of CCR2-dependent migration and activation of 
CX3CR1-dependent retention mechanisms, which together promote 
macrophage accumulation in vessel wall. Our results may explain at 
the molecular and cell biology levels the genetic link between 
CX3CR1 and atherosclerosis. Moreover, they identify macrophage 
binding to coronary artery smooth muscle cells as the first primary 
cell setting in which CX3CR1 functions as the major adhesion sys-
tem. 
 Thus, modulation of activation and function in macrophages 
might be a potential therapeutic target in attenuating the atheroscle-
rosis-based cardiovascular diseases.  
Role of Platelets  
 Beyond their role in hemostasis and thrombosis platelets are 
critically involved in the onset of atherosclerosis. Platelets represent 
an important linkage between inflammation, and atherogenesis. 
Platelets interact with inflammatory cells including leukocytes and 
endothelium. These interactions lead to leukocyte recruitment to-
wards the vascular wall, initiating extravasation of circulating 
mononuclear cells and foam cell generation. Inflammatory proc-
esses within the arterial wall result in development of atheroscle-
rotic lesions and atheroprogression. Inflammatory processes at the 
vascular wall result in the development of atherosclerosis. Platelet 
interactions with leukocytes may play a key role in the initiation of 
inflammation. They trigger autocrine and paracrine activation proc-
esses, leading to leukocyte recruitment (in)to the vascular wall. 
 The function of the endothelium is influenced by multiple fac-
tors as a consequence of cell-cell interactions. Cell-cell communica-
tion between endothelial cells with platelets has only recently begun 
to receive systematic study. In recent years it has been established 
that platelet-endothelial interactions are involved at all stages of 
atherosclerotic disease. From a mechanistic standpoint, platelets 
and endothelial cells communicate on multiple levels. Cross-talk 
may occur over a distance (paracrine signaling), via transient inter-
actions (so-called give-and-go mechanism), or through receptor-
mediated cell-cell adhesion. Platelets may release or transfer sub-
stances that influence endothelial cell function, and vice versa. 
Among many others, adhesion molecules, such as P-selectin 
(CD62P), are of special interest because of their role in modulating 
interactions between blood cells and the endothelium, and also 
because of the possible use of the soluble form as a plasma predic-
tor of adverse cardiovascular events.  
 Human monocytes adhere to activated platelets, resulting in the 
formation of platelet-monocyte complexes (PMC). Complex forma-
tion depends on the interaction between platelet-displayed P-
selectin and the specific ligand for P-selectin on leukocytes, P-
selectin glycoprotein ligand-1 (PSGL-1). We have recently shown 
that monocytes within PMC have increased adhesive capacity to the 
activated endothelium. To better understand the effect of platelet 
binding on the capacity of monocytes to adhere to activated endo-
thelium, the P-selectin-PSGL-1 interaction-induced changes in 
integrin functionality were studied. The binding of platelets to 
monocytes via P-selectin-PSGL-1 interactions was shown to in-
crease expression and activity of alpha4beta1 and alphaM-
beta2integrin, with a concomitant decrease in L-selectin expression. 
Furthermore, the binding of platelets to monocytes resulted in in-
creased monocyte adhesion to intercellular adhesion molecule-1, 
vascular cell adhesion molecule-1, and fibronectin. Platelet binding 
was also responsible for an increase in monocyte transendothelial 
migration. Similar effects were observed after engagement of 
PSGL-1 with specific antibodies or with P-selectin immunoglobulin 
protein. Our data suggest that platelets, by binding via P-selectin to 
PSGL-1 on monocytes, induce up-regulation and activation of beta1 
and beta2integrins and increased adhesion of monocytes to acti-
vated endothelium. Hence, monocytes within PMC are in a higher 
state of activation and may have, therefore, an increased athero-
genic capacity. 
 The ability of platelets to activate and aggregate to form blood 
clots in response to endothelial injury, such as plaque rupture, is 
well established. These cells are therefore important contributors to 
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ischaemia in atherothrombosis, and antiplatelet therapy is effective 
for this reason. However, growing evidence suggests that platelets 
are also important mediators of inflammation and play a central role 
in atherogenesis itself. Interactions between activated platelets, 
leukocytes and endothelial cells trigger autocrine and paracrine 
activation signals, resulting in leukocyte recruitment at and into the 
vascular wall. Direct physical interaction may contribute also, 
through platelet adhesion molecules assisting localization of mono-
cytes to the site of atherogenesis and platelet granule release con-
tributing to the chronic inflammatory milieu which leads to foam 
cell development and accelerated atherogenesis. Recent studies 
have shown that antiplatelet therapy in animal models of acceler-
ated atherogenesis can lead to decreased plaque size and improve 
plaque stability. 
Interactions among Endothelial Cells, Monocytes, and T Cells  
 A hallmark of atherogenesis is the upregulation of endothelial 
cell adhesion molecules (CAMs) and concomitant recruitment of 
monocytes. In atherosclerosis process molecules form on the endo-
thelium that are responsible for the adherence, migration, and ac-
cumulation of monocytes and T cells. Such adhesion molecules, 
which act as receptors for glycoconjugates and integrins present on 
monocytes and T cells, include several selectins, intercellular adhe-
sion molecules, and vascular-cell adhesion molecules. progression 
of atherosclerosis is currently believed to involve the interaction of 
monocytes with the vascular endothelium. Within the last decade, 
the cell-surface proteins thought to control these interactions have 
been investigated.  
 It begins with the stages of atherogenesis from the movement of 
the monocyte to the endothelium, followed by the migration of 
smooth muscle cells from the media to the intima, and subsequently 
to the later stages of fibrofatty plaque formation and potential com-
plications due to thrombosis and/or plaque fissure and embolism 
[104]. Molecules associated with the migration of leukocytes across 
the endothelium, such as platelet-endothelial-cell adhesion mole-
cules, [105] act in conjunction with chemoattractant molecules 
generated by the endothelium, smooth muscle, and monocytes — 
such as monocyte chemotactic protein 1, osteopontin, [106] and 
modified LDL — to attract monocytes and T cells into the artery. 
 The recruitment of circulating monocytes occurs via a tightly 
regulated multi-step process mediated by a combination of cell 
surface adhesion molecules. Initially, activated endothelial cells at 
sites of incipient atherosclerosis express P-selectin, which mediates 
the tethering and rolling of circulating monocytes. P-selectin binds 
to P-selectin glycoprotein ligand-1 (PSGL-1) and other glycosy-
lated ligands on monocytes SGL-1, the dominant ligand for all three 
selectins, is only functional when properly glycosylated. PSGL-1 
binds P-selectin in the presence of fucosyl transferase, sialyl trans-
ferase, core 2 GlcNAc transferase and sulfatyl transferase activities 
[107]. All these enzymes are constitutively expressed in monocytes 
[108], yielding constitutively active PSGL-1. There is some evi-
dence that E-selectin is also inducibly expressed at sites of athero-
sclerosis [109], and E-selectin deficiency in ApoE-null mice had a 
modest effect on lesion development compared to ICAM-1 and P-
selectin deficiency [110]. However, functional data in relevant 
models that would directly support a role for this molecule are lack-
ing. 
 Under normal blood flow, selectin-mediated interactions are not 
sufficient to arrest rolling leukocytes. It is now evident that select-
ins not only allow the capturing and rolling of leukocytes on the 
endothelium, but they also signal through PSGL-1 to activate in-
tegrins and induce monocyte activation [111]. Integrins are het-
erodimeric cell surface receptors and support both rolling and adhe-
sion of leukocytes. Upon activation, integrins undergo a series of 
conformational changes that result in increased binding affinity for 
their respective ligands [112]. 
 Atherosclerotic lesions are thought to start by subendothelial 
low-density lipoprotein (LDL) accumulation, which leads to endo-
thelial cell (EC) activation and chronic inflammation. The endothe-
lium is the primary barrier between blood and tissues. However, 
ECs are susceptible and sensitive to the shear stresses provided by 
blood flow, which can change their morphology and trigger many 
signaling cascades [113]. LDL accumulation preferentially occurs 
at sites of arterial branching or curvature, where flow is disturbed, 
in contrast to areas of continuous laminar flow, which are not or 
less affected. There is a positive correlation between areas of low 
shear stress and sites of LDL accumulation and lesion initiation 
[114]. Hyperlipidemia, due to both genetic and environmental fac-
tors increases the risk of atherosclerosis, as greater circulating LDL 
levels lead to increased accumulation. platelet activation promotes 
the adhesive interaction between monocytes and endothelial cells 
during atherosclerosis. It is believed that aggregation of activated 
platelets with circulating monocytes promotes monocyte-endo-
thelial interactions by deposition of proinflammatory chemokines 
and P-selectin expression [115] Indeed, CCL5 deposition by plate-
lets on activated endothelium induces arrest of rolling monocytes 
[116,119]. In addition, the combination of platelet-derived platelet 
factor 4 (PF4/CXCL4) with CCL5 results in an effect greater than 
CCL5 alone. Furthermore, P-selectin-mediated rolling of activated 
platelets on inflamed endothelium is important for the progression 
of atherosclerotic lesions. Although some ECs express functional 
PSGL-1 [117], the endothelial ligand for platelet P-selectin in athe-
rosclerotic lesions is unknown. P-selectin-expressing platelets in-
jected into Apoe/ mice accelerated the formation of atheroscle-
rotic lesions [118], whereas injection of P-selectin-deficient plate-
lets resulted in smaller lesions. This finding is supported by bone 
marrow transplantation experiments suggesting that platelet and not 
endothelial P-selectin drives atherosclerosis. Recently, Tsou et al. 
[120] aimed to understand how endothelial cells sense a gradient of 
fluid shear stress and transduce signals that regulate membrane 
expression of cell adhesion molecules and monocyte recruitment. In 
this study human aortic endothelial cells were stimulated with TNF-
alpha and simultaneously exposed to a linear gradient of shear 
stress that increased from 0 to 16 dyne/cm2. Cell adhesion molecule 
expression and activation of NFkappa B were quantified by im-
munofluorescence microscopy with resolution at the level of a sin-
gle endothelial cell. Monocyte recruitment was imaged using cus-
tom microfluidic flow chambre. VCAM-1 and E-selectin upregula-
tion was greatest between 2-4 dyne/cm2 (6 and 4-fold, respectively) 
and above 8 dyne/cm2 expression was suppressed below that of 
untreated endothelial cells. In contrast, ICAM-1 expression and 
NFkappa B nuclear translocation increased with shear stress up to a 
maximum at 9 dyne/cm2. Monocyte recruitment was most efficient 
in regions where E-selectin and VCAM-1 expression was greatest. 
On this basis authors found that the endothelium can sense a change 
in shear stress on the order of 0.25 dyne/cm2 over a length of ap-
proximately 10 cells, regulating the level of protein transcription, 
cellular adhesion molecule expression, and leukocyte recruitment 
during inflammation.  
 In certain pathological conditions, such as atherosclerosis, en-
dothelial function is chronically disturbed, and this alteration is a 
critical step in the progression of the disease. In recent years, ad-
vances in knowledge have improved our understanding of the 
physiopathology of atherosclerosis, which is now known to be a 
dynamic and progressive process proceeding from endothelial dys-
function and inflammation of the vascular wall. The evolution and 
prognosis of atherosclerosis, along with the efficacy of therapeutic 
modalities, can be assessed by measuring the circulating levels of 
various biomarkers expressed or released by the endothelium. 
 Platelets represent an important linkage between inflammation, 
thrombosis, and atherogenesis. Inflammation is characterized by 
interactions among platelets, leukocytes, and ECs. These interac-
tions trigger autocrine and paracrine activation processes that lead 
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to leukocyte recruitment into the vascular wall. Platelet-induced 
chronic inflammatory processes at the vascular wall result in devel-
opment of atherosclerotic lesions and atherothrombosis. 
 During the adhesion process, platelets become activated and 
release an arsenal of potent inflammatory and mitogenic substances 
into the local microenvironment, thereby altering chemotactic, ad-
hesive, and proteolytic properties of ECs [121].  
These platelet-induced alterations of the endothelial phenotype 
support chemotaxis, adhesion, and transmigration of monocytes to 
the site of inflammation. Released from dense granules, -granules, 
lysosomes, the canalicular system, or the cytosol, platelets secrete 
or expose adhesion proteins (e.g, fibrinogen, fibronectin, vWF, 
thrombospondin, vitronectin, P-selectin, GPIIb/IIIa), growth factors 
(e.g, PDGF, TGF-, EGF, bFGF), chemokines (e.g, RANTES, 
platelet factor 4 [CXC chemokine ligand 4], epithelial neutrophil-
activating protein 78 [CXC chemokine ligand 5]), cytokine-like 
factors (e.g, IL-1, CD40 ligand, thromboglobulin), and coagulation 
factors (e.g, factor V, factor XI, PAI-1, plasminogen, protein S). 
These proteins act in a concerted and finely regulated manner to 
influence widely differing biological functions such as cell adhe-
sion, cell aggregation, chemotaxis, cell survival and proliferation, 
coagulation, and proteolysis, all of which accelerate inflammatory 
processes and cell recruitment. For example, IL-1 has been identi-
fied as a major mediator of platelet-induced activation of ECs 
[122.]. The IL-1 activity expressed by platelets appears to be asso-
ciated with the platelet surface, and coincubation of ECs with 
thrombin-activated platelets induces IL-1-dependent secretion of 
IL-6 and IL-8 from ECs [123]. Furthermore, incubation of cultured 
ECs with thrombin-stimulated platelets significantly enhances the 
secretion of endothelial monocyte chemoattractant protein-1 (MCP-
1) in an IL-1-dependent manner. MCP-1 belongs to the CC family 
of chemokines and is thought to play a key role in the regulation of 
monocyte recruitment to inflamed tissue and in atherosclerosis 
[124,125]. 
 Moreover, A finely regulated functional interaction of platelets 
with chemokines has also been implicated in atherogenesis [126]. 
Activated platelets can release chemokines and can induce the se-
cretion of chemokines in various cells of the vascular wall; in turn, 
certain chemokines can enhance platelet aggregation and adhesion 
in combination with primary agonists and can trigger monocyte 
recruitment. One such candidate for monocyte recruitment is RAN-
TES, which has been shown to trigger monocyte arrest on inflamed 
and atherosclerotic endothelium [127]. Deposition of platelet-
derived RANTES induces monocyte recruitment mediated by P-
selectin [128]. Another platelet-derived chemokine is platelet factor 
4 (PF4), the most abundant protein secreted by activated platelets. 
First, PF4 acts as a chemoattractant for monocytes promoting their 
differentiate on into macrophages [129]. Second, PF4 may directly 
aggravate the atherogenic actions of hypercholesterolemia by pro-
moting the retention of lipoproteins. 
 Sachais and colleagues have recently shown that PF4 can facili-
tate the retention of LDL on cell surfaces by inhibition of its degra-
dation by the LDL receptor [130]. In addition, PF4 markedly en-
hances the esterification and uptake of oxidized LDL by macro-
phages [131]. 
 With the help of intravital microscopy and the availability of 
appropriate atherosclerotic animal models, it has become evident 
that platelets adhere to the arterial wall in vivo even in the absence 
of EC denudation [132]. Theilmeier and coworkers found in hyper-
cholesteremic rabbits that platelets adhere to predilection sites of 
atherosclerosis before lesions are detectable [133]. 
 Substantial platelet adhesion to the carotid artery early in 
atherogenesis involved both platelet GPIb and IIb). Platelet ad-
hesion to the carotid wall coincided with inflammatory gene ex-
pression and preceded the invasion of leukocytes [134]. Prolonged 
antibody blockade of platelet GPIb profoundly reduced leukocyte 
accumulation in the arterial intima and attenuated atherosclerotic 
lesion formation. Moreover, apoEdeficient mice lacking GPIIb 
exhibit substantially reduced formation of atherosclerotic lesions 
[135]. Further, circulating activated platelets and platelet-
leukocyte/monocyte aggregates promote formation of atheroscle-
rotic lesions [136]. The importance of P-selectin for atherosclerotic 
lesion development has also been described [137-139]. The impor-
tance of platelets in development of atherosclerosis is also docu-
mented by Belton et al, who showed that inhibition of COX-1, an 
enzyme that is exclusively present in platelets, prevented gross 
lesion formation in apoE-/- mice [140]. Interestingly, effective in-
hibition of downstream activation cascades can also effectively 
inhibit atherosclerosis in various models. The body of evidence 
implicating the CD40-CD40L system in atherogenesis is compel-
ling:  
 Disruption of CD40-CD40L in mouse models of atherosclerosis 
both downregulated early disease events such as initial plaque for-
mation [141,142] and could halt the progression of established le-
sions to more advanced unstable lesions [143].  
 In humans an increase in systemic platelet activation has been 
described for a variety of atherosclerotic diseases, including coro-
nary artery disease [144], transplant vasculopathy [145], and carotid 
artery disease [146]. Recently, it was found that activation of circu-
lating platelets is associated with enhanced wall thickness of the 
carotid artery in humans [147]. 
 On this basis several lines of evidence indicate that platelets 
are potent inflammatory cells that induce inflammatory responses in 
adjacent cells such as leukocytes and endothelial cells. Platelets 
may also themselves respond to inflammatory mediators produced 
by these neighboring cells. These platelet-mediated inflammatory 
pathways contribute to atherogenesis in both the early and late stage 
of the process. 
Platelets not only play a role in the late complications of atheroscle-
rosis, but are also essential in its initiation, interacting with endo-
thelial cells and leukocytes. Platelet adhesion to injured or athero-
sclerotic vessels is critical for the initiation of atherosclerotic lesion 
formation in vivo. Increasing evidence has recently highlighted the 
role of progenitor cells in inflammation, atherogenesis, and athero-
progression. Recruitment of progenitor and dendritic cells to sites 
of vascular injury is poorly understood so far. Both human progeni-
tor and dendritic cells [148] significantly adhere to platelets, indi-
cating that platelets adherent to collagen or to endothelial cells can 
serve as a bridging mechanism directing circulating progenitor and 
dendritic cells to sites of impaired vasculature. Moreover, platelets 
regulate differentiation of progenitor cells to endothelial cells or 
macrophages and foam cells and modulate essential functions of 
dendritic cells, including their activation, differentiation and apop-
tosis in vitro.  
 Recruitment of human CD34+ progenitor cells toward vascular 
lesions and differentiation into vascular cells has been regarded as a 
critical initial step in atherosclerosis. To investigate whether plate-
lets are involved in progenitor cell recruitment and differentiation 
into endothelial cells and foam cells, Daub et al. [149] examined 
the interactions of platelets and CD34+ progenitor cells. Cocultiva-
tion experiments showed that human platelets recruit CD34+ pro-
genitor cells via the specific adhesion receptors P-selectin/PSGL-1 
and beta1- and beta2-integrins. Furthermore, platelets were found to 
induce differentiation of CD34+ progenitor cells into mature foam 
cells and endothelial cells. Platelet-induced foam cell generation 
could be prevented partially by HMG coenzyme A reductase inhibi-
tors via reduction of matrix metalloproteinase-9 (MMP-9) secre-
tion. Finally, agonists of peroxisome proliferator-activated receptor-
alpha and -gamma attenuated platelet-induced foam cell generation 
and production of MMP-9. This study describes a potentially im-
portant mechanism of platelet-induced foam cell formation and 
generation of endothelium in atherogenesis and atheroprogression. 
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The understanding and modulation of these mechanisms may offer 
new treatment strategies for patients at high risk for atherosclerotic 
diseases. 
 The bidirectional interaction between platelets and other cells 
may also be involved in the nonresolving inflammation characteriz-
ing atherosclerosis. In patients with atherosclerotic disorders, plate-
let-mediated inflammation appears to be operating in spite of the 
wide use of platelet-inhibiting drugs. 
 On this basis nevertheless, platelets are generally not believed 
to be involved in the initiation of atherosclerosis. more recently The 
involvement of platelets in the initiation of atherosclerotic lesion 
formation had become critical in directing the atherosclerotic proc-
ess into regeneration or ongoing vascular injury. 
 Platelets internalize oxidized phospholipids and promote foam 
cell formation. Platelets also recruit circulating blood cells includ-
ing progenitor cells to the vessel, that are able to differentiate into 
foam cells or endothelial cells depending on conditions. Platelets 
express various scavenger receptors that are able to regulate LDL-
uptake. LDL-laden platelets are internalized by adherent progenitor 
cells that in turn differentiate into macrophages and foam cells. 
 An expanding body of evidence continues to build on the role 
of platelets as initial actors in the development of atherosclerotic 
lesions. Platelets bind to leukocytes, endothelial cells, and circulat-
ing progenitor cells and initiate monocyte transformation into 
macrophages. Therefore platelets regulate the initiation, develop-
ment and total extent of atherosclerotic lesions. 
MICROBES, INFLAMMATION AND ATHEROSCLEROSIS 
 Among the multiple factors involved in the pathophysiology of 
heart disease, infections have been proposed to play a role in athe-
rosclerosis with most of the available evidence implicating 
Chlamydia pneumonia, influenza virus and Mycoplasma pneumo-
niae. Based on a model case presentation, we speculate that in the 
absence of traditional risk factors and in the context of an ongoing 
respiratory infection caused by a pro-inflammatory pathogen (M. 
pneumoniae) along with a past positive serologic history for poten-
tially proven atherogenic microorganism (C. pneumoniae) and in-
fection may elicit potentially pathogenic events on vascular wall 
cells and leukocytes of atheromatous lesions, supporting the hy-
pothesis that such infections may potentiate atherosclerotic cardio-
vascular disease (CVD). 
 The recognition of atherosclerosis as an inflammatory disease 
in its genesis, progression and ultimate clinical manifestations has 
created an interesting area of vascular research. Apart from those 
well-known traditional risk factors for atherosclerosis, novel and 
potentially treatable atherosclerotic risk factors such as homocys-
teine (an amino acid derived from the metabolism of dietary me-
thionine that induces vascular endothelial dysfunction) and infec-
tions have emerged. In fact, the century-old 'infectious' hypothesis 
of atherosclerosis has implicated a number of micro-organisms that 
may act as contributing inflammatory stimuli. Although cytomega-
lovirus, Helicobacter pylori and Chlamydia pneumoniae are the 
three micro-organisms most extensively studied, this review will 
focus on C. pneumoniae. Collaborative efforts from many disci-
plines have resulted in the accumulation of evidence from seroepi-
demiological, pathological, animal model, immunological and anti-
biotic intervention studies, linking C. pneumoniae with atheroscle-
rosis. Seroepidemiological observations provide circumstantial 
evidence, which is weak in most prospective studies. Pathological 
studies have demonstrated the preferential existence of C. pneumo-
niae in atherosclerotic plaque tissues, while animal model experi-
ments have shown the induction of atherosclerosis by C. pneumo-
niae. Finally, immunological processes whereby C. pneumoniae 
could participate in key atherogenic and atherothrombotic events 
have also been identified. Although benefits of the secondary pre-
vention of atherosclerosis have been demonstrated in some antibi-
otic intervention studies, a number of negative studies have also 
emerged.  
 Atherosclerosis can be apparently the result of ultrachronic 
persistent infection by Chlamydia pneumoniae and not the result of 
different risk factors. The main arguments for the chlamydial gene-
sis are: 1) Correlation of coronary heart disease and other athero-
sclerotic disease with antibodies against C. pneumoniae; 2) C. 
pneumoniae could be detected with different techniques (PCR, 
immunohistology, electromicroscopy, culture) in a high percentage 
in atheromas from different sites; 3) Three international studies 
with macrolides in coronary heart disease were successful; 4) The 
target cells of atherosclerosis (endothelia, macrophages, muscle 
cells) can be infected by C. pneumoniae in vitro; 5. Positive animal 
experiments. 
 The Koch-Henle criteria for the proof of the etiology are largely 
fulfilled--even if there are doubts about the validity of these criteria 
in chronic local infections. A number of unexplainable aspect of 
atherosclerosis can be seen in a new light. The higher incidence of 
coronary heart disease in young males has a parallel in the remark-
able androtropism of many bacterial diseases (pneumococcal 
pneumonia, tuberculosis). The reduction of incidence of atheroscle-
rotic diseases since 1965 can be explained by the much higher in-
take of doxycyclin and macrolides. The low incidence of coronary 
heart disease in France--sometimes regarded as an effect of red 
wine--can be explained as a result of a much higher use of antich-
lamydial antibiotics. The increase of inflammatory parameters (C-
reactive protein, fibrinogen, leucocytes) before acute coronary in-
farction are not risk factors but signs of an active chronic infection. 
The interpretation is possible, that atherogenic changes in lipids like 
increase of LDL and decrease of HDL are not risk factors but con-
sequence of chronic arterial infection by chlamydia. The low inci-
dence of atherosclerosis in the tropics--despite high frequency of 
chlamydial infection--is difficult to explain. Vascular infection can 
be related with the age of the patient at the primary infection. With 
low hygiene, intestinal primary infections in early childhood can be 
possible. Arterial infection would be thus a result of a primary in-
fection in adolescence ("yet another poliomyelitis story"). There are 
good arguments for the thesis that C. pneumoniae is the primary 
cause of atherosclerosis and not a secondary invader. The conse-
quence, nevertheless, is similar: Antibiotics get a key role. The 
macrolides roxithromycin, azithromycin, clarithromycin and the 
tetracyclin doxycyclin fulfill the criteria as potential antichlamydial 
agents. In general a longer treatment (6 to 8 to 12 weeks) seems 
advisable. It is necessary to start international studies with antibiot-
ics in coronary infarction and other clinical manifestations of athe-
rosclerosis. The relevant antibiotics licensed for chlamydial infec-
tions are cheap and safe.  
 Song et al. [150] hypothesized that a vascular infection with C. 
pneumoniae may induce a chronic inflammatory reaction in the host 
vascular tissue and activated inflammatory cells may express in-
flammatory mediators such as cyclooxygenase-2 (COX-2) and ma-
trix metalloproteinases (MMPs). At first, we evaluated the relation-
ship between C. pneumoniae infection and atherosclerosis indi-
rectly by serologic study, and then, to confirm our hypothesis, we 
performed an immunohistochemical study of atherosclerotic 
plaques. The seropositive rate of anti-Chlamydia pneumoniae IgG 
was higher in the disease group (Group I, 59.8%, n = 254) than in 
the negative control group (Group III, 47.4%, n = 97) (p = 0.041), 
but the anti-Chlamydia pneumoniae IgA was not different in sero-
positivity between the two groups (Group I, 64.6%; Group III, 
57.7%). The simultaneous seropositive rates of both IgG and IgA 
were 56.7% in Group I and 43.3% in Group III (p = 0.033). In sub-
groups without the conventional risk factors of atherosclerosis, 
these findings were more prominent. Furthermore, we performed 
immunohistochemical staining on the atherosclerotic aortic tissues 
obtained from patients that were seropositive to C. pneumoniae (n = 
5), by using antibodies to C. pneumoniae, COX-2, and MMP-9. The 
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immunoreactivity for COX-2 and MMP-9 increased in the athero-
sclerotic plaques itself, predominantly in the surrounding area of 
immunoreactive C. pneumoniae. These findings support our hy-
pothesis and C. pneumoniae may participate in a pathogenetic 
mechanism for atherogenesis or progression of atherosclerosis.  
 Furthermore, Blasi et al. [151] studied 51 patients (mean age, 
68.3 years) who underwent abdominal aortic aneurysm surgery. For 
each patient authors performed a microimmunofluorescence test for 
immunoglobulin G (IgG), IgA, and IgM antibodies to C. pneumo-
niae specific antigen (TW-183). Anti-H. pylori antibodies were 
determined by means of an EIA-G test. Each aortic aneurysm surgi-
cal specimen was sampled into multiple sections of 0.3 cm2 each 
and frozen at -20 degrees C. Two samples of each aneurysm were 
used for a nested PCR with two sets of C. pneumoniae and two sets 
of H. pylori specific primers. Specimens were treated with a solu-
tion containing 20 mM Tris-HCl, Tween 20-Nonidet P-40 (0.5% 
[vol/vol] each), and 100 micrograms of proteinase K per ml and 
incubated at 60 degrees C for 1 h and at 98 degrees C for 10 min. 
DNA was extracted twice with phenol-chloroform-isoamylic alco-
hol and precipitated with sodium acetate-ethanol by standard meth-
ods. Forty-one patients were seropositive for C. pneumoniae with 
past-infection patterns in 32 patients (16 < or = IgG < 512; 32 < or 
= IgA < 256) and high antibody titers in 9 patients (IgG > or = 
512). In 26 of 51 patients, C. pneumoniae DNA was detected in 
aortic aneurysm plaque specimens. Of these patients, 23 had a sero-
logic past-infection pattern, 2 had an acute reinfection pattern, and 
1 was seronegative. Forty-seven of 51 patients were seropositive for 
H. pylori. In all cases PCR showed no evidence of H. pylori pres-
ence in plaque specimens. This study provides data on a possible C. 
pneumoniae involvement in the pathogenesis of aortic aneurysm 
and additional evidence for an association between this agent and 
atherosclerosis.  
 Mayr M et al. [152] evaluated cardiovascular risk factors as 
well as seropositivity to Chlamydia pneumoniae, Helicobacter py-
lori, and cytomegalovirus in a population-based study. A significant 
association between prevalence and severity of atherosclerosis in 
carotid and femoral arteries and IgA antibodies to C pneumoniae 
was demonstrated that was not substantially altered after adjustment 
for established risk factors. For anti-H pylori IgG antibodies, sig-
nificant correlations to vascular disease were restricted to low social 
status and lesions in carotid arteries. In addition, the study design 
allowed us to monitor lesion progression over time. In this prospec-
tive analysis, C pneumoniae seropositivity emerged as a significant 
risk predictor. Antibody titers against cytomegalovirus were not a 
marker for prevalence or incidence of atherosclerosis in this popula-
tion. Further infection parameters added to the predictive value of 
chlamydial serology in risk assessment. Mean odds ratios for the 
prevalence of carotid atherosclerosis were 4.2 and 6.3 for seroposi-
tive subjects with elevated C-reactive protein levels and clinical 
evidence for chronic respiratory infection, respectively. For subjects 
with all 3 infection parameters, the odds ratio of carotid atheroscle-
rosis reached 10.3 (P<0.0001). Concomitantly, serum antibodies to 
mycobacterial heat-shock protein 65 (mHSP65) correlated with 
seropositivity to C pneumoniae and H pylori but not to cytomega-
lovirus. This prospective population-based study provides strong 
evidence for a potential atherogenic role of persistent bacterial in-
fection, especially C pneumoniae, as indicated by serological and 
clinical data and demonstrates a correlation between immune reac-
tions to mHSP65 and bacterial infections in atherogenesis. 
Genetic Susceptibility and Inflammatory Gene Polymorphisms 
in Atherogenesis 
 Development of atherosclerotic plaques represents a complex 
interplay of environmental risk factor exposure and a multigenic 
profile with intermediate phenotypes. It is becoming more widely 
accepted that individual patient phenotypic variants in plaque insta-
bility is unexplained solely by risk factor exposure and that differ-
ences in distribution of polymorphisms in genes coding for inflam-
matory factors may account for the patterns of behavior in carotid 
atherosclerotic. 
 Several studies showed a profile of genetic markers and single 
nucleotide polymorphisms that define with greater specificity the 
susceptibility of an individual for atherosclerosis development 
based on gene presence as well as gene- gene interaction. Many of 
the genes that regulate inflammatory cytokine and adhesion mole-
cules are polymorphic in nature.  
 Plaque. Although large epidemiological studies confirm the 
hereditary contribution to cerebrovascular risk [153] the quantifica-
tion of genetic factors for large-vessel disease remains to be de-
fined. frequency of specific alleles for cytokines such as TNF- and 
IL-1 have been associated with other inflammatory diseases [154, 
155, 158]. 
 To explain the presence of these seemingly injurious proin-
flammatory gene polymorphisms, genes that increase proinflamma-
tory expression from an evolutionary prospective may have pro-
vided an advantage to our ancestors, including allowance for wound 
healing and eradication of infection during periods of nutritional 
deprivation. These same genes may now confer selective disadvan-
tages in modern times, particularly given the average life span in-
creases, environmental stresses, and western diet/lifestyle that could 
lead to insulin resistance and atherosclerosis [156-158]. 
 Numerous gene polymorphisms associated with the develop-
ment of coronary and carotid atherosclerotic disease have now been 
identified. For example, a large population-based study revealed a 
strong association in the gene encoding phosphodiesterase 4D 
(PDE4D) for carotid and cardiogenic stroke. Haplotype identifica-
tion was essential for determining phenotypic expression. This gene 
revealed 3 distinct groups characterized by wild-type, at-risk, and 
protective haplotype classification [159]. Other genes showing 
significant association with the development of atherosclerotic dis-
ease include IL-1 receptor antagonist, in which the homozygous 
carrier state for allele 2 imparts an adjusted odds ratio (OR) of 
13.78 for a greater likelihood of atherosclerosis [160] Also, Toll-
like receptor-4 polymorphism Asp299Gly is associated with an 
alteration in inflammatory expression and acute coronary events 
[161]. 
 Moreover, current evidence favours an interaction of multiple 
environmental and genetic factors in the initiation and progression 
of AAA. Epigenetics is the term used to define the properties of the 
genome that are not explained by the primary sequence, but are due 
to the modifications of DNA and/or associated proteins. Previous 
research indicates the association of gene specific promoter DNA 
hyper-methylation and global DNA hypo-methylation with athero-
sclerosis. Evidence also suggests an important role for epigenetic 
processes such as histone acetylation in cardiovascular diseases 
including atherosclerosis and restenosis. Altered DNA methylation 
or histone acetylation occur in inflammation, cellular proliferation 
and remodelling processes and therefore maybe relevant to the pa-
thology of AAA. Important risk factors for AAA, including ciga-
rette smoking, older age, male gender and hypertension, have been 
linked with epigenetic effects and thus could act in this way to 
promote AAA. In this review, we discuss the potential role of epi-
genetic mechanisms in AAA. Since epigenetic alterations are to 
some extent reversible, further study of this area may identify new 
treatment targets for AAA. 
 Jerrard-Dunne P et al. [162] examined the impact of inflamma-
tory gene polymorphisms and gene-smoking interactions on com-
mon carotid artery intima-media thickness (IMT), a measure of 
early atherosclerosis. In a community population (n=1000), mean 
IMT was determined using ultrasound. This population was geno-
typed for 6 polymorphisms in 4 inflammatory genes: IL-6-174, IL-
6-572, and IL-6-597; IL-1-beta-31; IL-1 receptor antagonist VNTR 
and CD14-159. Serum IL-6 levels were measured in the first 500 
subjects. Genotypes/haplotypes associated with higher IL-6 levels 
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were designated "inflammatory haplotypes. A gene load score was 
calculated, in which 2 represented individuals homozygous for > or 
=2 inflammatory genotypes/haplotypes and 0 was homozygous for 
none. Increasing gene load of inflammatory genotypes was associ-
ated with a linear increase in serum IL-6 levels (P=0.018) and in-
creased carotid artery IMT (P=0.003). There was a significant inter-
action between gene load and smoking status on carotid IMT (P for 
interaction=0.002). Specifically, in smokers, carriers of inflamma-
tory haplotypes had significantly increased age- and sex-adjusted 
IMT (IL-6-174C/IL-6-572G/IL-6-597A, P=0.005; IL-1-beta-
31T/IL-1RN*2,P=0.04; CD14-159CC, P=0.028). These findings 
support the hypothesis that inflammation and cytokine responses 
provide a key mechanism by which smoking causes atherogenesis. 
Secondly, they highlight the importance of gene-environment, and 
gene-gene-environment interactions in the pathogenesis of athero-
sclerosis. 
 Another study extended [163] the analysis by inclusion of other 
inflammatory conditions (chronic infection and obesity/abnormal 
glucose tolerance). In this study common carotid and femoral artery 
IMT was determined in the Bruneck Study population (n=810). 
Proinflammatory variants were determined in 3 genes (IL-6 [-174C, 
-572G, -597A haplotype], IL-1-receptor antagonist [VNTR *2], and 
endotoxin receptor CD-14 [-159C]). There was a significant rela-
tionship between gene-variant score and carotid IMT: age- and sex-
adjusted mean IMT in subjects with 0, 1, and >or=2 gene variants 
was 936, 987 and 1047 microm, respectively (P=0.001), and syner-
gistic effects of gene-variant score and smoking on IMT measure-
ments (P=0.040). Analogous findings were obtained for obe-
sity/abnormal glucose tolerance and chronic infection. Interactive 
effects of gene-variant score and a risk factor score composed of the 
acquired inflammatory conditions were highly significant (P<0.001 
each). Results were similar for femoral artery IMT. 
 These results provide support for a causal role of inflammation 
in carotid atherosclerosis, and emphasize the importance of gene-
gene and gene-environment interactions in this pathogenic pathway. 
This may help to explain the substantial variability of disease ex-
pression in subjects with proinflammatory risk factors such as 
smoking, diabetes and chronic infection. 
 Given the important role of Ang II/Ang 1-7 in atherogenesis, 
Thomas et al. [164] investigated the impact of ACE2 deficiency on 
the development of atherosclerosis. C57Bl6, Ace2 knockout (KO), 
apolipoprotein E (ApoE) KO and ApoE/Ace2 double KO mice 
were followed until 30 weeks of age. Plaque accumulation was 
increased in ApoE/Ace2 double KO mice when compared to ApoE 
KO mice. This was associated with increased expression of adhe-
sion molecules and inflammatory cytokines, including interleukin-
6, monocyte chemoattractant protein-1, and vascular cell adhesion 
molecule-1, and an early increase in white cell adhesion across the 
whole aortae on dynamic flow assay. In the absence of a proathero-
sclerotic (ApoE KO) genotype, ACE2 deficiency was also associ-
ated with increased expression of these markers, suggesting that 
these differences were not an epiphenomenon. ACE inhibition pre-
vented increases of these markers and atherogenesis in ApoE/ACE2 
double KO mice. Bone marrow macrophages isolated from Ace2 
KO mice showed increased proinflammatory responsiveness to 
lipopolysaccharide and Ang II when compared to macrophages 
isolated from C57Bl6 mice. Endothelial cells isolated from Ace2 
KO mice also showed increased basal activation and elevated in-
flammatory responsiveness to TNF-. Similarly, selective inhibition 
of ACE2 with MLN-4760 also resulted in a proinflammatory phe-
notype with a physiological response similar to that observed with 
exogenous Ang II (10(-7) mol/L). 
 Genetic Ace2 deficiency is associated with upregulation of 
putative mediators of atherogenesis and enhances responsiveness to 
proinflammatory stimuli. In atherosclerosis-prone ApoE KO mice, 
these changes potentially contribute to increased plaque accumula-
tion. These findings emphasize the potential utility of ACE2 reple-
tion as a strategy to reduce atherosclerosis. 
 Tenascin-C (TNC) is an extracellular matrix protein implicated 
in biological processes important for atherosclerotic plaque devel-
opment and progression, including smooth muscle cell migration , 
proliferation and inflammation. Very recently Minear et al. [165] 
investigated whether common genetic variation within TNC is as-
sociated with risk of atherosclerosis and coronary artery disease 
(CAD) in three independent datasets. Authors genotyped 35 single 
nucleotide polymorphisms (SNPs), including 21 haplotype tagging 
SNPs, in two of these datasets: human aorta tissue samples 
(n = 205) and the CATHGEN cardiovascular study (n = 1,325). 
Eleven of these 35 SNPs were then genotyped in a third dataset, the 
GENECARD family study of early-onset CAD (n = 879 families). 
Three SNPs representing a block of linkage disequilibrium, 
rs3789875, rs12347433, and rs4552883, were significantly associ-
ated with atherosclerosis in multiple datasets and demonstrated 
consistent, but suggestive, genetic effects in all analyses. In com-
bined analysis rs3789875 and rs12347433 were statistically signifi-
cant after Bonferroni correction for 35 comparisons, p = 2  10(-6) 
and 5  10(-6), respectively. The SNP rs12347433 is a synonymous 
coding SNP and may be biologically relevant to the mechanism by 
which tenascin-C influences the pathophysiology of CAD and athe-
rosclerosis. This is the first report of genetic association between 
polymorphisms in TNC and atherosclerosis or CAD. 
 F11R is the gene name for an adhesion protein, called the F11-
receptor, aka JAM-A, which under normal physiological conditions 
is expressed constitutively on the surface of platelets and localized 
within tight junctions of endothelial cells (EC). Previous studies of 
the interactions between human platelets and EC suggested that 
F11R/JAM-A plays a crucial role in inflammatory thrombosis and 
atherosclerosis. A study by Babinska et al. [166] reported a ob-
tained in-vivo confirmation o by investigating F11R/JAM-A protein 
and mRNA in patients with aortic and peripheral vascular disease 
and in an animal model of atherosclerosis. Molecular and im-
munofluorescence determinations revealed very high levels of 
F11R/JAM-A mRNA and F11R/JAM-A protein in atherosclerotic 
plaques of cardiovascular patients. Similar results were obtained 
with 12-week-old atherosclerosis-prone apoE-/- mice, an age in 
which atherosclerotic plaques are well established. Enhanced ex-
pression of the F11R/JAM-A message in cultured EC from human 
aortic and venous vessels was observed following exposure of the 
cells to cytokines. Determinations of platelet adhesion to cultured 
EC inflamed by combined cytokine treatment in the presence of 
F11R/JAM-A - antagonists provided data indicating that de novo 
expression of F11R/JAM-A on the luminal surface of inflamed EC 
has an important role in the conversion of EC to a thrombogenic 
surface. Further studies of these interactions under flow conditions 
and under in-vivo settings could provide a final proof of a causal 
role for F11R/JAM-A in the initiation of thrombosis.  
 On the basis of this study that have determined that the F11 
receptor (F11R; aka JAM-A) exerts a critical force in the adhesion 
of human platelets to inflamed endothelial cells (ECs), and thus can 
play a significant role in the initiation of atherosclerotic plaque 
formation, the same group of researchers focused on a subsequent 
event in plaque development--the migration of smooth muscle cells 
(SMCs) from the media to the intima of inflamed vessels. Authors 
investigated [167] of the expression of F11R in atherosclerotic ar-
teries of coronary artery disease (CAD) patients, and of the role of 
F11R in the migration of SMCs involved in atherogenesis. His-
tological staining and specific-antibody immunofluorescence of 
excised, human atherosclerotic coronary arteries revealed the ex-
pression of F11R in the SMCs of the intima. RT-PCR and SDS-
PAGE followed by immunoblotting procedures demonstrated that 
F11R mRNA and the F11R protein levels were enhanced by the 
stimulation of cultured human aortic SMCs with a combined treat-
ment of proinflammatory cytokines (TNFalpha+INFgamma+IL-
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beta1). Neither the F11R message nor protein was expressed in 
non-stimulated SMCs. The functional role of F11R in SMCs' mi-
gration was studied in cytokine-stimulated SMCs by interference of 
F11R expression with siRNA. Silencing of the F11R gene of cyto-
kines-treated SMCs inhibited the expression of both F11R mRNA 
and F11R protein. Functionally, silencing of the F11R gene blocked 
the proliferation and migration of these inflamed SMCs, both criti-
cal events in atherogenesis. 
 The new findings of this study are that F11R mRNA and F11R 
protein are expressed in SMCs of the intima (but not in the media) 
of atherosclerotic arteries of CAD patients, and that F11R is re-
quired for the proliferation and migration of inflamed SMCs. Based 
on these findings, we conclude that in addition to the previously 
reported role of F11R in the initiation of plaque formation, F11R 
plays also an important role in the subsequent growth of atheroscle-
rotic plaques. Identification of drugs that interfere with these patho-
physiologic actions of F11R thus represents an effective new ap-
proach for the prevention and treatment of atherosclerosis, heart 
attacks and stroke. 
 Serum chemokine CXC Ligand 16 (CXCL16) concentration is 
associated with atherosclerosis and CXCL16 expression may be 
influenced by the polymorphismA181V, Wang et al. [168] estab-
lished whether serum CXCL16 concentration or the A181V geno-
type is more strongly associated with atherosclerotic stroke and its 
associated risk factor, carotid atherosclerosis. Authors used PCR-
RFLP to genotype 244 atherosclerotic stroke patients (AS group), 
153 stroke-free controls (patient controls) and 167 healthy controls. 
Serum CXCL16 concentration was determined for a subset of pa-
tients (n=135) and all controls. The same subset of patients was 
then examined using ultrasound to evaluate their carotid atheroscle-
rotic lesions, including intima-media thickness (IMT), plaque sta-
bility and carotid plaque area (CPA). Compared with the patient 
controls and healthy controls, serum CXCL16 concentration was 
significantly increased in the AS group (P < 0.05, and 0.01). It was 
also strongly associated with increased IMT, vulnerable plaque and 
increased CPA (P < 0.05, < 0.001, and < 0.01). However, the 
CXCL16 A181V genotype distribution and allele frequencies 
showed no differences between AS and control groups, nor did it 
influence serum CXCL16 concentration. Authors concluded that 
serum CXCL16 concentration is significantly associated with athe-
rosclerotic stroke and carotid atherosclerosis, suggesting that this 
biochemical test may be useful to identify patients at increased risk 
of atherosclerosis. 
CELL TRAFFICKING IN ATHEROSCLEROTIC LESIONS  
 The accumulation of smooth muscle cells (SMCs) plays a prin-
cipal role in atherogenesis, post-angioplasty restenosis and trans-
plantation-associated vasculopathy. Therefore, much effort has 
been expended in targeting the migration and proliferation of me-
dial smooth muscle cells to prevent occlusive vascular remodeling. 
Recent evidence suggests that bone marrow-derived circulating 
precursors can also give rise to endothelial cells and smooth muscle 
cells that contribute to vascular repair, remodeling, and lesion for-
mation under physiological and pathological conditions. 
 It has been assumed that smooth muscle cells derived from the 
adjacent medial layer migrate, proliferate and synthesize extracellu-
lar matrix. Although much effort has been devoted, targeting migra-
tion and proliferation of medial smooth muscle cells, no effective 
therapy to prevent occlusive vascular remodeling has been estab-
lished. It was suggested that bone marrow cells may have the poten-
tial to give rise to vascular progenitor cells that home in the dam-
aged vessels and differentiate into smooth muscle cells or endothe-
lial cells, thereby contributing to vascular repair, remodeling, and 
lesion formation. 
 Fischietti et al. [169] evaluated in 2 groups of diabetic or non-
diabetic Wistar rats the occurrence of basal or stimulated stable 
adherence to the endothelial layer and extravasation of circulating 
fluorescently-labelled leukocytes was assessed by using an in vivo 
videomicroscopy technique. In a second part of the study, the de-
velopment of vascular damage in short term diabetes was studied in 
the genetically C6 deficient rats of the PVG strain, and compared 
with those observed in the wild-type C6 sufficient animals. Here, 
the analysis of mesentery vascular expression of mRNA for vascu-
lar cell adhesion molecule (VCAM)-1, transforming growth factor-
 (TGF-), connective tissue growth factor (CTGF), and platelet-
derived growth factor (PDGF), the evaluation of intravascular pro-
tein levels of VCAM-1, TGF-, CTGF, proliferative cell nuclear 
antigen (PCNA), as well as the assessment of structural changes 
and Complement components deposition at the mesentery arterial 
vascular wall were also performed.: Leukocyte trafficking, mesen-
tery arteries hypertrophy, extracellular matrix deposition, local 
vascular gene and protein expression of VCAM-1, TGF-, CTGF 
and PCNA, as well as PGDF gene expression were all increased by 
short term diabetes, but all significantly reduced in the C6 deficient 
diabetic animals, thus suggesting an active role for TCC in the de-
velopment of vascular inflammation in the early phases of experi-
mental diabetes. 
 Furthermore, recent studies have shown that hematopoietic 
bone marrow (BM) cells participate in the formation of different 
types of plaques, such as hyperlipidemia-induced atherosclerosis 
and transplant-associated vasculopathy [170,171].  
Excessive accumulation of smooth-muscle cells (SMCs) has a key 
role in the pathogenesis of vascular diseases. It has been assumed 
that SMCs derived from the outer medial layer migrate, proliferate 
and synthesize extracellular matrix components on the luminal side 
of the vessel. Although much effort has been devoted to targeting 
migration and proliferation of medial SMCs, there is no effective 
therapy that prevents occlusive vascular remodeling. We show here 
that in models of post-angioplasty restenosis, graft vasculopathy 
and hyperlipidemia-induced atherosclerosis, bone-marrow cells 
give rise to most of the SMCs that contribute to arterial remodeling. 
Notably, purified hematopoietic stem cells differentiate into SMCs 
in vitro and in vivo. Our findings indicate that somatic stem cells 
contribute to pathological remodeling of remote organs, and may 
provide the basis for the development of new therapeutic strategies 
for vascular diseases through targeting mobilization, homing, dif-
ferentiation and proliferation of bone marrow-derived vascular 
progenitor cells. 
 Studies using chimeric animals revealed that bone marrow de-
rived cells exist at the sites of vascular healing and lesion formation 
after injury. High-resolution histological analyses revealed that 
those bone marrow derived cells do express some markers for endo-
thelial cells or smooth muscle cells. Peripheral mononuclear cells 
could differentiate into endothelial-like cells or smooth muscle like 
cells in vitro according to the culture conditions. 
 Circulating progenitors significantly contribute to vascular re-
pair and lesion formation. These findings provide the basis for the 
development of new therapeutic strategies that involve targeting the 
mobilization, homing, differentiation, and proliferation of bone 
marrow- derived vascular progenitor cells. 
 In a study by Qiu et al. [171] authors attempted to use MRI to 
monitor, in vivo, trafficking of magnetically. labeled BM cells to 
atherosclerotic lesions BM-derived cells from LacZ-transgenic 
mice were labeled with a uperparamagnetic MR contrast agent, 
Feridex, and then transplanted into ApoE-/- recipient mice (n=25) 
with an atherogenic diet for approximately 7-9 weeks. Histological 
examination revealed formations of atherosclerotic plaques in 17 
cases and neointimal hyperplasia in 8 cases. Ex vivo high-resolution 
MR imaging demonstrated details of plaque structure, which was 
correlated with histology confirmation In Group I with Feridex-
labeled BM cell transplantation, in vivo MR imaging showed larger 
MR signal voids of the aortic walls (due to the “blooming” effect of 
Feridex) in four cases, in which Feridex- and/or LacZ-positive cells 
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were detected with histochemistry. No such findings were visual-
ized in the two control animal groups. In the eight cases with inti-
mal hyperplasia, no larger MR signal voids of the aortic walls were 
detected by in vivo MR imaging. In this study authors presented a 
potential method of using MRI to monitor, in vivo, trafficking of 
magnetically labeled bone marrow cells to atherosclerotic lesions, 
which may provide a useful tool to guide the targeting of hema-
topoietic cells for gene therapy- or chemotherapy-based interven-
tions in atherosclerotic cardiovascular disease. 
 The mobilization and recruitment of bone marrow derived or 
resident progenitor cells giving rise to smooth muscle cells have 
been implicated in accelerated forms of primary plaque formation 
and neointimal hyperplasia after arterial injury. By contrast, con-
vincing evidence has emerged that the arterial homing of endothe-
lial progenitor cells contributes to endothelial recovery and thereby 
limits neointimal growth after endothelial denudation. In the 
chronic context of primary atherosclerosis, plaque progression and 
destabilization, a more complex picture has become apparent. 
Clinically, the number and function of endothelial progenitor cells 
have been linked with an improved endothelial function or regen-
eration and have been frequently inversely correlated with cardio-
vascular risk (factors). In animal models, however, the injection of 
bone marrow cells or endothelial progenitor cells, as well as the 
application of stem-cell mobilizing factors, have been associated 
with an exacerbation of atherosclerosis and unstable plaque pheno-
type, whereas the contribution of smooth muscle progenitors to 
primary atherosclerosis appears to be more confined to supporting 
plaque stability.Considering the balance between distinct circulat-
ing vascular progenitor cells and identifying mechanisms for selec-
tive control of their mobilization and homing appears crucial to 
improve prediction and to directly modulate endogenous vascular 
remodeling processes. 
 Recruitment of monocytes into atherogenic foci is required for 
the onset and progression of atherosclerosis. In lesions, monocyte-
derived cells take up modified lipoprotein and produce secretory 
factors that attract and activate smooth muscle cells, other immune 
cells, and more monocytes. Mechanisms that attract monocytes to 
lesions are partly defined [172-174] but relatively little is known 
about the fate of monocytes once they migrate into lesions. Many 
begin to differentiate into lipid-laden macrophage foam cells, but it 
has also been recently appreciated that a substantial population of 
lesional foam cells in humans and animals bears features of den-
dritic cells (DCs), rather than macrophages. 
 Because tissue macrophage homeostasis is not maintained in 
atherosclerotic lesions, but instead macrophages accumulate 
abundantly in plaques along with cells resembling DCs, Liodrà et 
al. examined herein whether the increase of monocyte-derived cells 
in atherosclerotic plaques might result not only from robust 
recruitment of monocytes into lesions, but also from a depressed 
rate of their migratory clearance from the lesions. Thus, we 
examined rates of emigration of human monocyte-derived cells out 
of a model of a vessel wall in the presence or absence of 
proatherogenic lipids and then compared migratory clearance of 
monocyte-derived cells from murine atherosclerotic lesions under 
conditions in which plaques regressed or progressed. these findings 
underscore a so-far unknown alteration in the cellular trafficking 
that distinguishes atherosclerotic lesions that regress compared with 
those that continue to progress and suggest that interventions to 
maintain functional pathways of emigration out of lesions may 
favor disease regression and quell plaque progression.  
 The presence of B cells in the adventitia of atherosclerotic arter-
ies was described as early as 1981 [175], and CD22+ B cells were 
found in early fatty streak-type lesions and full-blown atheroscle-
rotic plaques of apolipoprotein-E-defi cient (ApoE/) mice [176]. 
Although the impact of B cells on atherosclerosis development was 
not appreciated for a long time, recent studies show that B cell defi 
ciency increases atherosclerosis in LDL-receptor/ (8) or 
ApoE/ mice [177]. The atheroprotective effect of B cells may be 
related to natural antibodies (Abs) produced by distinct sets of in-
nate-like B cells, B1 cells, and marginal zone B cells [178]. 
 Atherosclerosis is a chronic inflammatory disease of the arterial 
wall and an increasing body of evidence suggests that the immune 
system actively participates in the initiation, progression and persis-
tence of atherosclerosis. Different types of leukocytes such as T and 
B lymphocytes, natural killer cells (NK) and NKT cells, macro-
phages, dendritic cells and mast cells have been found within athe-
rosclerosis-prone aortas. The mechanisms of monocyte recruitment 
have been partially characterized and involve P-selectin, E-selectin, 
VCAM-1, ICAM-1 and JAM-A. CXCL1, CCL5, CXCL4, CXCL7 
and MIF are also implicated in monocyte trafficking into aortas. 
Recently it has been reported that Ly6C(high) and Ly6C(low) 
monocyte subsets differently use CCL2, CX3CL1 and CCL5 for 
their homing into atherosclerotic aortas. T and B lymphocytes con-
stitutively migrate into the normal and atherosclerotic aortic wall in 
an L-selectin-dependent manner. Recent studies suggest an impor-
tant role of CCL5, CXCL10, CXCL16, CXCR6 and MIF in T cell 
influx into the atherosclerotic wall. However, there is little informa-
tion available on the mechanisms of recruitment of other types of 
the immune cells such as NK, NKT and mast cells. In this review 
we shall summarize what is known about leukocyte recruitment into 
the aortic wall during atherosclerosis with a focus on mouse model 
systems. 
 Although numerous reports have described the involvement of 
different leukocyte types in atherosclerosis, few studies investigated 
the cell composition of the normal aorta [179, 180]. 
 Galkina et al. [181] reported that T and B cells reside within the 
adventitia of normal/noninfl amed aortas as a consequence of con-
stitutive homing that is partially L-selectin dependent. authors used 
a newly developed flow cytometry-based method to quantitatively 
investigate the alterations of immune cell composition that occurs 
during the development and progression of atherosclerosis in 
ApoE/ mice, during which tertiary lymphoid tissue is formed in 
the adventitia of the aortas. 
 Flow cytometry of aortic cell suspensions showed that B and T 
lymphocytes and some macrophages and dendritic cells are already 
present in the adventitia of normal/noninflamed mouse aortas. 
Adoptively transferred lymphocytes constitutively homed to the 
aorta and resided within the adventitia up to 7 d after transfer. 
Lymphocyte trafficking into normal/noninflamed or atherosclero-
sis-prone aortas was partially L-selectin dependent. Antigen-
activated dendritic cells induced increased T lymphocyte prolifera-
tion within the aorta 72 h after adoptive transfer. During progres-
sion of atherosclerosis in apolipoprotein-E-deficient mice, the total 
number of macrophages, T cells, and dendritic cells, but not B cells, 
increased significantly. This alteration in immune cell composition 
was accompanied by the formation of tertiary lymphoid tissue in 
the adventitia of atherosclerotic aortas. These results demonstrate 
that lymphocytes already reside within the normal/noninflamed 
aorta before the onset atherosclerosis as a consequence of constitu-
tive trafficking. Atherosclerosis induces the recruitment of macro-
phages and dendritic cells that support antigen presentation. 
 Though substantial information is available on immune cells in 
atherosclerotic lesions of the lamina intima, cells in the lamina ad-
ventitia have received less attention. In a study by Moos et al. [182] 
The composition of immune cells in the innominate artery and ab-
dominal aorta was examined in young, adult, and old apolipoprotein 
(apo) E(-/-) and wild-type mice on standard mouse chow. In the 
innominate artery of apoE(-/-) mice, adventitial T cells increased at 
32, 52, and 78 weeks exceeding those of the intima by 6-, 24-, and 
85-fold. Single T cells dominated in young mice, later T/B cell 
clusters emerged, and lymphoid-like structures reminiscent of in-
flammatory follicles formed preferentially in the abdominal aorta of 
old mice. Follicles contained organized sets of immune response-
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regulating cells: Interdigitating dendritic cells, T cell effectors, 
proliferating B cells, and plasma cells. Adventitial T cell inflamma-
tion was associated with a marked increase in transcripts of the 
chemokine MIP-1alpha in the aorta but not in spleen or liver. Ad-
ventitial lymphocyte infiltration and formation of inflammatory 
follicle-like structures in the abdominal aorta of old apoE(-/-) mice 
point to the adventitia as a site of local adaptive immune reactions 
during atherogenesis in hyperlipidemic mice. 
 Recently, it has been shown that stem/progenitor cells may 
repair damaged/lost endothelial cells in vein grafts and wire-injured 
arteries. Recently some authors [183] investigated endothelial cell 
turnover and regeneration in apolipoprotein E (apoE)(-/-)/transgenic 
mice carrying LacZ genes driven by an endothelial TIE2 promoter. 
To assess cell proliferation on the surface of aortas in apoE(-/-) 
mice and wild-type controls, BrdU was injected into the tail vein 
and labeled on en face preparation. BrdU-positive cells on the aor-
tas were observed occasionally in wild-type mice and frequently at 
sites prone to lesion development in apoE(-/-) mice (0.18+/-0.1% 
versus 1.12+/-0.2%; P<0.001). Endothelial integrity tests demon-
strated that the areas with high rate of cell turnover displayed Evans 
blue leakage, low levels of VE-cadherin expression, and increased 
cell attachment, as evidenced by Evans blue dye injection, immu-
nostaining, and scanning electron microscopy, respectively. Fur-
thermore, immunostaining for CD34, Sca-1, Flk-1, and CD133 
indicated that approximately 3% to 5% of total cells on the aorta 
were positive in apoE(-/-) mice. En face double labeling using Ki-
67 and progenitor markers revealed that 30% to 50% of progeni-
tor(+) cells expressed Ki-67, indicating a state of proliferation. To 
clarify the origin of endothelial progenitor cells participating in 
endothelial repair in apoE(-/-) mice, a chimeric mouse model was 
created by bone marrow transplantation between apoE(-/-) and 
LacZ(+/+)/apoE(-/-) mice. Ten months after bone marrow trans-
plantation, approximately 3% to 4% of total cells in the lesion-
prone areas were beta-gal positive in apoE(-/-) with apoE(-/-)/TIE2-
LacZ bone marrow mice. When cells of aortas from chimeric mice 
were cultivated on Matrigel-coated plates, a capillary-like structure 
was found, which showed beta-gal/CD31 or beta-gal/von Wille-
brand factor double positivity. By a combined analysis of laser 
dissection microscopy and nest reverse transcription polymerase 
chain reaction, it was found that beta-gal(+) cells were mainly ex-
pressing CD31 and CD144. These findings provide the first quanti-
tative data on endothelial turnover and repair by progenitor cells 
that are, at least in part, derived from bone marrow during devel-
opment of atherosclerosis in apoE(-/-) mice. 
 Moreover, Atherosclerosis is largely attributed to chronic vas-
cular injury, as occurs with excess cholesterol; however, the effect 
of concomitant vascular aging remains unexplained. We hypothe-
size that the effect of time in atherosclerosis progression is related 
to obsolescence of endogenous progenitor cells that normally repair 
and rejuvenate the arteries. 
 Some authors [184] showed that chronic treatment with bone 
marrow-derived progenitor cells from young nonatherosclerotic 
ApoE-/-mice prevents atherosclerosis progression in ApoE-/- re-
cipients despite persistent hypercholesterolemia. In contrast, treat-
ment with bone marrow cells from older ApoE-/- mice with athero-
sclerosis is much less effective. Cells with vascular progenitor po-
tential are decreased in the bone marrow of aging ApoE-/- mice, but 
cells injected from donor mice engraft on recipient arteries in areas 
at risk for atherosclerotic injury.These data indicate that progressive 
progenitor cell deficits may contribute to the development of athe-
rosclerosis. 
 On this basis aging may the most powerful risk for the devel-
opment of atherosclerosis and atherosclerotic thromboembolic 
complications. Yet, the mechanism by which aging affects the arte-
rial wall and its deterioration has remained essentially uncharacter-
ized. Chronic injuries to the arterial wall contribute to the develop-
ment of atherosclerosis. However, it is important to note that a 
complex repair system that involves both local and bone marrow-
derived cells maintains arterial homeostasis and integrity. The age-
dependent failure of the bone marrow to produce vascular progeni-
tor cells responsible for such arterial repair--an inability that results 
from the impact of a lifetime of risk factors such as hyperlipidemia-
-drives atherosclerosis and its thromboembolic complications. As a 
consequence of such failure, the normal processes of arterial wall 
repair and rejuvenation are impaired. The disequilibrium that en-
sues between injury of the arterial wall and repair leads to athero-
sclerotic inflammation and consequent thromboembolic complica-
tions. The bone marrow and derived progenitor cells represent key 
regulators of atherosclerosis, and progress in the prevention and 
treatment of atherosclerosis and its thromboembolic complications 
will need to take into account this new dimension for the disease 
process. 
 A novel concept [185] for atherosclerosis risk implicates a lack 
of endothelial progenitor cell (EPC)-dependent arterial repair in the 
development of the disease that is secondary to exhaustion of re-
pair-competent EPCs. Molecular evidence derived from genetic 
techniques indicates atherosclerotic lesions may begin to form as 
arterial repair fails, rather than merely following arterial injury. 
Thus, chronic arterial injury may overwhelm the ability of EPCs to 
maintain arterial homeostasis, particularly when EPCs capable of 
arterial repair become exhausted. Recent studies have reported 
genes identified using non-biased approaches (ie, genetic linkage 
studies and genome-wide association studies) that are associated 
with susceptibility for atherosclerosis and related thromboembolic 
disorders; these genes may be implicated in the control of arterial 
wall inflammation and EPC-mediated tissue repair. Most of the 
genes identified by using non-biased genomic techniques are asso-
ciated with inflammation, immune response and stem cells. This 
review focuses on new genetic data in the field of atherosclerosis 
and arterial homeostasis. 
 Recent studies of bone marrow (BM)-transplanted apoE knock-
out (apoE-/-) mice have concluded that a substantial fraction of 
smooth muscle cells (SMCs) in atherosclerosis arise from circulat-
ing progenitor cells of hematopoietic origin. This pathway, how-
ever, remains controversial. Bentzon et al. [186] reexamined the 
origin of plaque SMCs in apoE-/- mice by a series of BM transplan-
tations and in a novel model of atherosclerosis induced in surgically 
transferred arterial segments. Authors analyzed plaques in lethally 
irradiated apoE-/- mice reconstituted with sex-mismatched BM 
cells from eGFP+ apoE-/- mice, which ubiquitously express en-
hanced green fluorescent protein (eGFP), but did not find a single 
SMC of donor BM origin among approximately 10,000 SMC pro-
files analyzed. We then transplanted arterial segments between 
eGFP+ apoE-/- and apoE-/- mice (isotransplantation except for the 
eGFP transgene) and induced atherosclerosis focally within the 
graft by a recently invented collar technique. No eGFP+ SMCs 
were found in plaques that developed in apoE-/- artery segments 
grafted into eGFP+ apoE-/- mice. Concordantly, 96% of SMCs 
were eGFP+ in plaques induced in eGFP+ apoE-/- artery segments 
grafted into apoE-/- mice. These experiments show that SMCs in 
atherosclerotic plaques are exclusively derived from the local vessel 
wall in apoE-/- mice. 
 On this basis, antigen presentation may also occur within the 
atherosclerotic plaque (yellow on the right), which is rich in antigen 
presenting cells (APC: macrophages and dendritic cells). 
Continuous trafficking of immune cells between the inflamed 
atherosclerotic artery and the lymphoid organs may be necessary to 
mount an adaptive immune response. 
CONCLUSIONS  
 Atherosclerosis is nowadays recognized as a chronic inflamma-
tory disease of large arteries. 
 Atherosclerotic cardiovascular disease is the leading cause of 
death in industrialised countries and is quickly becoming the 
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principal cause of death worldwide. For a long time, atherosclerosis 
was considered as a simple accumulation of lipids that would 
gradually obstruct the arteries leading to myocardial infarction and 
stroke. However, it was recently shown by many investigators 
including myself that atherosclerosis has an inflammatory basis. 
This discovery offers the opportunity to develop novel therapeutic 
strategies targeting the inflammatory component of the disease. 
This paradigm change was paralleled by the growing awareness that 
the majority of patients with rheumatoid arthritis and other 
inflammatory diseases die of premature cardiovascular diseases. 
The earliest changes in atherogenesis occur in the arterial endothe-
lium. For reasons that are not entirely clear, the endothelium be-
comes more permeable to lipoproteins and immune system cells 
such as monocytes, T lymphocytes and leukocytes. The migration 
of these immune cells into arterial walls is mediated by oxidized 
low-density lipoprotein (LDL), cytokines and other blood factors. 
(Fatty streaks consisting of lipid- and cholesterol-rich monocytes, 
macrophages and T lymphocytes begin to form in arteries. This 
process is stimulated by the adherence and aggregation of platelets 
and by several mediators of the inflammatory response, including 
growth factors, cytokines such as interleukin-1 and tumor necrosis 
factor, and thrombaxane A2 an eicosanoid derived from arachidonic 
acid. Refer to the table for a list of key inflammatory mediators.  
 With continued inflammation, the fatty streaks progress to ad-
vanced, complicated lipid-filled lesions. Eventually, a fibrous cap 
forms. Formation of the fibrous cap represents a healing response to 
the injury and is mediated by the actions of interleukin-1, tumor 
necrosis factor and other cytokines. When the advanced lesion be-
comes unstable, the plaque ruptures, causing a thrombosis that may 
result in myocardial infarction or stroke. 
 Several authors reported that when the mixed cell population 
contained within human atherosclerotic lesions is cultured in vitro, 
displays a dysregulated production of cytokines and chemokines in 
the absence of exogenous stimuli. Dyregulated inflammation in 
atherosclerotic plaques may be explained either by the persistence 
of pro-inflammatory stimuli or by the failure to resolve 
inflammation. Our research aims to characterise the molecular 
events of the dysregulated inflammation within the atherosclerotic 
plaques, and to identify strategies for its downregulation.  
 The use of biomarkers expressed by inflammatory cells, and 
especially circulating biomarkers, has gained a lot of attention be-
cause of their ability to reflect disease progression and predict the 
risk of a cardiovascular event. However, until now, no biomarkers, 
have been found that can detect high-risk patients with a good posi-
tive prognostic value. Therefore, novel sources of biomarkers are 
needed and one of the high-potential sources are circulating cells. 
Because macrophages play a crucial role in the development of 
atherosclerosis, a high focus has been placed on its precursor, the 
circulating monocyte. Recently it has become clear that the expres-
sion patterns of circulating monocytes changes in response to al-
terations in the diseased vessel wall, and multiple markers ex-
pressed by circulating monocytes have already been associated with 
disease progression like TLR, TNF and IL-8. But more research 
and large trials are needed. With the circulating cell program of the 
CTMM project the expression of biomarkers on circulating mono-
cytes and others cells will be investigated. Furthermore, a biosensor 
will be developed that is capable of measuring these biomarkers, so 
the development and progression of atherosclerotic disease and the 
identification of high-risk patients will be more accurate and easy to 
measure. 
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